Armata Pharmaceuticals (ARMP) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 25, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	AmpliPhi Biosciences Corp
Entity Central Index Key	921,114
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	APHB
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Public Float			$ 37,554,000
Entity Common Stock, Shares Outstanding		5,883,503

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 9,370,000	$ 6,581,000
Accounts receivable	125,000	100,000
Prepaid expenses and other current assets	521,000	339,000
Total current assets	10,016,000	7,020,000
Property and equipment, net	1,131,000	1,220,000
In process research and development	12,446,000	12,446,000
Acquired patents, net	338,000	369,000
Goodwill	7,562,000	7,562,000
Total assets	31,493,000	28,617,000
Current liabilities
Accounts payable, accrued expenses and other	1,464,000	1,167,000
Deferred revenue	245,000	244,000
Accrued severance	308,000	457,000
Dividends payable	368,000
Total current liabilities	2,385,000	1,868,000
Series B preferred stock derivative liability	1,493,000	12,320,000
Warrant liability	6,000	5,826,000
Accrued severance		98,000
Deferred tax liability	3,005,000	3,078,000
Total liabilities	6,889,000	23,190,000
Series B redeemable convertible preferred stock
$0.01 par value, 10,000,000 shares authorized, 7,527,853 shares issued and outstanding at December 31, 2015 and 8,671,040 shares issued and outstanding at December 31, 2014 (liquidation preference of $13,383,000 and $14,042,000 at December 31, 2015 and December 31, 2014, respectively)	11,890,000	1,990,000
Stockholders' equity
Common stock, $0.01 par value, 670,000,000 shares authorized, 5,883,503 shares issued and outstanding at December 31, 2015 and 3,983,182 shares issued and outstanding at December 31, 2014	59,000	40,000
Additional paid-in capital	375,177,000	365,403,000
Accumulated deficit	(362,522,000)	(362,006,000)
Total stockholders' equity (deficit)	12,714,000	3,437,000
Total liabilities, Series B redeemable convertible preferred stock and stockholders' equity	$ 31,493,000	$ 28,617,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Series B redeemable convertible preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Series B redeemable convertible preferred stock, shares authorized	10,000,000	10,000,000
Series B redeemable convertible preferred stock, shares issued	7,527,853	8,671,040
Series B redeemable convertible preferred stock, shares outstanding	7,527,853	8,671,040
Series B redeemable convertible preferred stock liquidation preference	$ 13,383,000	$ 14,042,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	670,000,000	670,000,000
Common stock, shares issued	5,883,503	3,983,182
Common stock, shares outstanding	5,883,503	3,983,182

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 475,000	$ 409,000
Operating expenses
Research and development	3,992,000	5,805,000
General and administrative	6,421,000	6,850,000
Severance expense	289,000	1,864,000
Total operating expenses	10,702,000	14,519,000
Loss from operations	(10,227,000)	(14,110,000)
Other income (expense)
Change in fair value of warrant liability	610,000	9,455,000
Change in fair value of Preferred B stock derivative liability	9,330,000	27,764,000
Other expense	302,000
Other income (expense), net	9,638,000	37,219,000
(Loss) income before taxes	(589,000)	23,109,000
Income tax benefit	73,000
Net income	(516,000)	23,109,000
Accretion of Series B redeemable convertible preferred stock	(10,278,000)	(1,285,000)
Net (loss) income attributable to common stockholders	$ (10,794,000)	$ 15,757,000
Per share information:
Net (loss) income per share of common stock - basic	$ (1.99)	$ 4.21
Weighted average number of shares of common stock outstanding - basic	5,411,204	3,746,639
Net (loss) income per share of common stock - diluted	$ (1.99)	$ (2.33)
Weighted average number of shares of common stock outstanding - diluted	5,411,204	5,886,730
Scenario, Previously Reported [Member]
Other income (expense)
Net (loss) income attributable to common stockholders		$ 21,824,000
Per share information:
Net (loss) income per share of common stock - basic		$ 5.82
Weighted average number of shares of common stock outstanding - basic		3,746,639
Net (loss) income per share of common stock - diluted		$ 3.37
Weighted average number of shares of common stock outstanding - diluted		6,472,093

Consolidated Statements of Rede

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Redeemable Convertible Preferred Stock Series B [Member]Series B redeemable convertible preferred stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balances at Dec. 31, 2013	$ 707,000	$ 36,000	$ 362,454,000	$ (385,115,000)	$ (22,625,000)
Balances (in shares) at Dec. 31, 2013	8,859,978	3,650,711
Net income (loss)				23,109,000	23,109,000
Accretion of dividends on Series B redeemable convertible preferred stock	$ 1,285,000		(1,285,000)		(1,285,000)
Warrants exercised		$ 1,000	1,594,000		1,595,000
Warrants exercised (in shares)		54,683
Conversion of Series B redeemable convertible preferred stock to common stock, value	$ (2,000)	$ 1,000	706,000		707,000
Conversion of Series B redeemable convertible preferred stock to common stock, shares	(188,938)	37,788
Stock-based compensation			775,000		775,000
Stock-based compensation - severance			1,161,000		1,161,000
Shares released from escrow		$ 2,000	(2,000)
Shares released from escrow (in shares)		240,000
Balances at Dec. 31, 2014	$ 1,990,000	$ 40,000	365,403,000	(362,006,000)	3,437,000
Balances (in shares) at Dec. 31, 2014	8,671,040	3,983,182
Net income (loss)				(516,000)	(516,000)
Accretion of dividends on Series B redeemable convertible preferred stock	$ 1,307,000		(1,307,000)		(1,307,000)
Amount reclassified to Series B redeemable convertible stock to accrete to its redemption value	8,971,000		(8,971,000)		(8,971,000)
Warrants exercised		$ 1,000	1,072,000		1,073,000
Warrants exercised (in shares)		56,645
Conversion of Series B redeemable convertible preferred stock to common stock, value	$ (378,000)	$ 2,000	1,504,000		1,506,000
Conversion of Series B redeemable convertible preferred stock to common stock, shares	(1,143,187)	228,637
Common stock issued in March 2015 financing, net of offering costs		$ 16,000	8,250,000		8,266,000
Common stock issued in March 2015 financing, net of offering costs (in shares)		1,575,758
Warrants reclassified from liabilities to equity due to amendment of warrants			5,462,000		5,462,000
Warrants reclassified from liabilities to equity due to increase in authorized shares			3,281,000		$ 3,281,000
Exercise of common stock options (shares)		39,281			214,815
Stock-based compensation			479,000		$ 479,000
Stock-based compensation - severance			4,000		4,000
Balances at Dec. 31, 2015	$ 11,890,000	$ 59,000	$ 375,177,000	$ (362,522,000)	$ 12,714,000
Balances (in shares) at Dec. 31, 2015	7,527,853	5,883,503

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net (loss) income	$ (516,000)	$ 23,109,000
Adjustments required to reconcile net income to net cash used in operating activities:
Change in fair value of warrant liability	(610,000)	(9,455,000)
Change in fair value of Series B preferred stock derivative liability	(9,330,000)	(27,764,000)
Gain on re-valuation of liquidated damages liability	(120,000)
Warrants issued to placement agents	213,000
Deferred taxes	(73,000)
Amortization of patents	31,000	31,000
Depreciation	299,000	127,000
Stock-based compensation	479,000	775,000
Stock-based compensation - severance	4,000	1,161,000
Changes in operating assets and liabilities net of acquisitions:
Accounts receivable	(25,000)	(92,000)
Accounts payable, accrued expenses, deferred revenue and other	296,000	(977,000)
Accrued severance	(247,000)	555,000
Prepaid expenses and other current assets	(182,000)	(42,000)
Net cash used in operating activities	(9,781,000)	(12,572,000)
Investing activities:
Purchases of property and equipment	(210,000)	(1,202,000)
Net cash used in investing activities	(210,000)	(1,202,000)
Financing activities:
Proceeds from warrant exercises	396,000
Proceeds from issuance of common stock, net	12,384,000
Net cash provided by financing activities	12,780,000
Net increase (decrease) in cash and cash equivalents	2,789,000	(13,774,000)
Cash and cash equivalents, beginning of period	6,581,000	20,355,000
Cash and cash equivalents, end of period	9,370,000	6,581,000
Supplemental schedule of non-cash financing activities:
Accretion of Series B redeemable convertible preferred stock	$ 10,278,000	1,285,000
Fair value of warrant liability upon issuance	4,210,000
Fair value of warrant liability converted upon exercise	$ 1,073,000	$ 1,595,000

Organization and Description of

Organization and Description of the Business	12 Months Ended
	Dec. 31, 2015
Organization and Description of the Business [Abstract]
Organization and Description of the Business	1. Organization and Description of the Business AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company is dedicated to developing novel antibacterial therapies called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets. The Company is a development stage company and has incurred net losses since its inception, has negative operating cash flows, and had an accumulated deficit of $362.5 million and $ 362.0 million as of December 31, 2015 and December 31, 2014 , respectively. The Company completed a $ 13.0 million private placement of its common stock in March 2015, which provided net proceeds of approximately $ 12.4 million after commissions to placement agents. In the opinion of management, the Company’s cash and cash equivalents are sufficient to fund its planned operations through the third quarter of 2016. This estimate is based on the Company’s current product development plans, projected staffing expenses, working capital requirements, and capital expenditure plans.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2015
Liquidity [Abstract]
Liquidity [Text Block]	2. Liquidity The Company has prepared the se consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception, has negative operating cash flows and has an accumulated deficit of $362.5 million as of December 31, 2015 , $ 47.0 million of which has been accumulated since January of 2011, when the Company began its focus on bacteriophage development. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. As of December 31, 2015 , the Company had cash and cash equivalents of $ 9.4 million. Management believes that our existing resources will be sufficient to fund our planned operations through the third quarter of 2016. The Company’s ability to raise additional funds will depend, in part, on the status of its product development activities and other business operations, as well as factors related to financial, economic, and market conditions, many of which are beyond its control. In addition, the Company has a disagreement with one of its principal stockholders, Third Security, LLC, regarding the interpretation of the Company’s Amended and Restated Articles of Incorporation. The disagreement relates to whether it is technically possible for the Company to satisfy the requirements for automatic conversion of the Company’s outstanding shares of Series B Redeemable Convertible Preferred Stock (Series B Preferred) pursuant to an underwritten public offering (a Qualified Public Offering). In the fourth quarter of 2015, Third Security informed the Company that, under its interpretation of the Amended and Restated Articles of Incorporation, the Qualified Public Offering conditions set forth in Article 4 of the Amended and Restated Articles of Incorporation can never be satisfied because the Company’s stock is publicly traded on the NYSE MKT, and that the only way all outstanding Series B Preferred can be converted into common stock is by obtaining the requisite consent of the Series B Preferred stockholders. The Company disagrees with Third Security’s interpretation. The Amended and Restated Articles of Incorporation also contain various other ambiguities, such as in the provisions relating to the conversion rate for converting Series B Preferred into common stock and the stated value of the Series B Preferred following the Company’s 50:1 reverse split of its common stock in August 2015. The stated value of the Series B Preferred affects other provisions of the Amended and Restated Articles of Incorporation, including the anti-dilution rights for the Series B Preferred as well as the minimum public offering price per share necessary for a public offering to satisfy one of the Qualified Public Offering conditions. These ambiguities, as well as Third Security’s interpretation of the Qualified Public Offering conditions, create uncertainty around the Company’s capital structure, which may adversely affect the Company’s ability to raise capital. The Company cannot be certain that sufficient funds will be available to it when required or on acceptable terms, if at all. If adequate funds are not available on a timely basis or on acceptable terms, the Company may be required to significantly reduce or refocus its operations or to obtain funds through additional arrangements that may require the Company to relinquish rights to certain of its products, technologies or potential markets, any of which could delay or require that it curtail or eliminate some or all of its development programs or otherwise have a material adverse effect on the business, financial condition and results of operations. This uncertainty around the Company’s ability to secure additional financing creates substantial doubt about its ability to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol Limited, Ampliphi d.o.o., and AmpliPhi Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated. Restatement of Prior Period Financial Statements The Company has determined that a restatement is required to the previously reported basic and diluted income ( loss ) per share for the year ended December 31, 2014 , three and six months ended June 30, 2014, three and nine months ended September 30, 2014 and three months ended June 30, 2015 . The correction has no impact on the Company’s consolidated balance sheets, statement of operations, or the consolidated statement of cash flows as previously reported for the aforementioned periods . Furthermore, the correction does not impact any other previously reported periods in 2014 and 2015 . The Company has not amended its previously-filed Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q for the periods affected by the restatement. The financial information related to basic and diluted income (loss) per share that has been previously filed or otherwise reported for these periods is superseded by the information in this Form 10-K, and the financial statements and related financial information contained in such previously-filed reports should no longer be relied upon. No other changes were made to these previously filed reports other than those disclosures related to basic and diluted income (loss) per share. The calculation of basic income (loss) per share requires consideration of the fact that the outstanding shares of the Company’s Series B redeemable convertible preferred stock , in certain limited circumstances, have the right to receive additional dividends beyond their accruing dividends and are consequently participating securities. Therefore, consideration of this component of the preferred stock terms is included in computing basic earnings per share pursuant to the two-class method. The Company failed to make such adjustments to the basic income (loss) per share calculations for the prior periods discussed above. The calculation of diluted income ( loss ) per share requires that , to the extent such securities are dilutive to income/loss per share for the period, an adjustment to net income ( loss ) used in the calculation is required to remove the change in fair value of the liability classified warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares. Similarly, the diluted income ( loss ) per share calculation also requires an adjustment to net loss used in the calculation to remove the change in fair value of the Series B redeemable convertible prefer red stock embedded derivative ( if the Series B redeemable convertible preferred stock is dilutive), including any applicable accretion, and an adjustment to the denominator is required to reflect the related dilutive securities. The Company failed to make such adjustments to the diluted income (loss) per share calculations for the prior periods discussed above. The table below illustrates a reconciliation of the components of the numerator and denominator included in the calculations of basic and diluted income (loss) per share and the impact of the correction of the error on the basic and diluted income (loss) per share amounts. Year Ended December 31, 2014 Basic income per share - as originally reported $ 5.82 Difference in basic income per share (1.61) Basic income per share - restated $ 4.21 Diluted loss per share - as originally reported $ 3.37 Difference in diluted loss per share (5.70) Diluted loss per share - restated $ (2.33) Numerator As originally reported $ 21,824,000 Correction - adjustment related to preferred stockholders' participation in the Company's undistributed earnings (6,067,000) Numerator for use in basic income per share, as restated 15,757,000 Correction - adjustments related to warrants and preferred stock (29,474,000) Numerator for use in diluted loss per share, as restated $ (13,717,000) Denominator As originally reported 6,472,093 Less antidilutive shares previously incorrectly included in denominator (585,363) Denominator for use in diluted loss per share, as restated 5,886,730 The denominator for the basic income per share calculation remains unchanged from the amount previously reported. The tables in Note 17 – Quarterly Financial Data illustrate a reconciliation of the components of the numerator and denominator included in the calculations of basic and diluted income ( loss ) per share for the three and six months ended June 30, 2014, three and nine months ended September 30, 2014 and the three months ended June 30, 2015 . Reverse Stock Split On August 3, 2015, the Company filed Articles of Amendment to Amended and Restated Articles of Incorporation with the Secretary of State of the State of Washington that effected a 1-for-50 (1: 50 ) reverse stock split of its common stock, par value $0.01 per share , effective August 7, 2015. On August 3, 2015, the Company also increased its authorized common stock, from 445,000,000 to 670,000,000 shares. The par value of its common stock was unchanged at $ 0.01 per share, post-split. All warrant, stock option, and per share information in the consolidated financial statements gives retroactive effect to the 1-for-50 reverse stock split that was effected on August 7, 2015. Use of Estimates Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: the determination of the fair value of stock-based awards, the fair value of liability-classified preferred stock derivatives, the fair value of liability-classified warrants, the valuation of long-lived assets, including in-process research and development (IPR&D), patents and goodwill, accrued expenses and the recoverability of the Company's net deferred tax assets and related valuation allowance. Cash and Cash Equivalents Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions. Cash equivalents include short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost plus accrued interest, which approximates fair market value. Accounts Receivable Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. As of December 31, 2015 and December 31, 2014 , management determined no allowance for doubtful accounts was required. Property and Equipment Property and equipment consists of computer and laboratory equipment, software, office equipment, furniture and leasehold improvements and is recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company’s estimated useful life for property and equipment is as follows: Estimated Useful Lives Laboratory equipment 5 – 7 years Office and computer equipment 1 – 5 years Leasehold improvements Shorter of lease term or useful life The Company reviews long-lived assets when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded since inception. Prepaid Expenses and Other Current Assets Prepaid and other current assets consist primarily of prepaid insurance, Australian government research grants receivable, deferred licensing costs, and deposits. In-Process Research & Development and Goodwill In-process research & development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized. The Company review s the carrying value of IPR&D and goodwill for potential impairment on an annual basis and at any time that events or business conditions indicate that it may be impaired. As permitted under Accounting Standards Codification Topic 350 (ASC 350), through December 31, 2015 , the Company elected to base its assessment of potential impairment on qualitative and quantitative factors , as applicable . The quantitative measure is based upon an estimate of future discounted cash flows. The discounted cash flows model indicates the fair value based on the present value of the cash flows expected to be generated in the future. Significant estimates in the discounted cash flows model include: the weighted average cost of capital; probability of success of research; expected future revenues from products; expected future operating costs; long-term rate of growth and profitability of the business; and working capital effects . Based on our assessment, IPR&D and goodwill were not impaired as of December 31, 2015 . Patents Patents are recorded at fair value and are amortized using the straight-line method over their estimated useful lives. During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents were acquired by the Company and patents in the amount of $ 493,000 were recorded. These patents are amortized over their useful life through December 2026. Annual patent amortization expense for the years ending December 31 are estimated as follows: Patent Amortization 2016 $ 31,000 2017 31,000 2018 31,000 2019 31,000 2020 31,000 Thereafter 183,000 Total patent amortization expense $ 338,000 Stock-Based Compensation The Company accounts for stock-based payments under the applicable accounting standard which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest. Warrants and Preferred Shares Conversion Feature Liabilities The Company accounts for both warrants with anti-dilution adjustment provisions and other features and preferred share features with anti-dilution adjustment provisions under the applicable accounting guidance which requires the warrant and the preferred share features to be recorded as liabilities and adjusted to fair value at each reporting period. Foreign Currency Translations and Transactions The functional currency of our wholly owned subsidiaries is the U.S. dollar. Revenue Recognition The Company generates revenue from technology licenses, collaborative research arrangements and agreements to provide research and development services. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees, royalties on product sales, and various other payments. The Company classifies advance payments received in excess of amounts earned as deferred revenue. Research and Development Costs Research and development costs include salaries, costs of outside collaborators and outside services, allocated facility, occupancy and utility expenses, which were partially offset by the benefit of Australian government research grants. The Company expenses research and development costs as incurred. Income Taxes Income taxes are recorded in accordance with the applicable accounting guidance which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the applicable accounting guidance. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2015 and 2014 , the Company does not have any significant uncertain tax positions. Basic and Diluted Net (Loss) Income per Common Share Basic net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders , less the impact under the two-class method of the preferred stockholders’ participation rights in the Company’s undistributed earnings, by the weighted average number of common shares outstanding during the period, excluding the dilutive effectors of preferred stock, warrants to purchase common shares, and stock options. Diluted net (loss) income per share of common stock is computed by dividing 1) the net (loss) income attributable to common stockholders, adjusted by income (loss) related to potential diluted preferred stock and warrants to purchase shares of our common stock by the sum of 2) the weighted average number of shares of common stock outstanding during the period plus the potential dilutive effects of preferred stock and warrants to purchase common stock and stock options outstanding during the period calculated in accordance with the treasury stock method, although these shares, options and warrants are excluded if their e ffect is anti-dilutive. T here was no difference between net loss and diluted net loss for the year ended December 31, 2015. Other Comprehensive Income (Loss) The Company recorded no comprehensive income other than net income for the periods reported. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The ASU creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2017. The Company has not yet evaluated the potential impact of adopting the guidance on its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes . The ASU is part of a simplification initiative aimed at reducing complexity in accounting standards. Current GAAP requires the deferred taxes for each jurisdiction (or tax-paying component of a jurisdiction) to be presented as a net current asset or liability and net noncurrent asset or liability. To simplify presentation, the new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The standard is effective for public entities for annual reporting periods beginning after December 15, 2016, and interim periods therein. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company's results of operations or liquidity. In February 2015, the FASB issued ASU 2016-02, Leases (Topic 842) , which amends the FASB Accounting Standards Codification and creates Topic 842, "Leases." The new topic supersedes Topic 840, "Leases," and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018. ASU 2016-02 mandates a modified retrospective transition method. The Company has not yet evaluated the potential impact of adopting the guidance on its consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern , which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities - Derivative Instruments	12 Months Ended
	Dec. 31, 2015
Fair Value of Financial Assets and Liabilities - Derivative Instruments [Abstract]
Fair Value of Financial Assets and Liabilities - Derivative Instruments	4. Fair Value of Financial Assets and Liabilities – Derivative Instruments ASC Topic 820, Fair Value Measurement (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:  Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.  Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.  Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification or ii) embody risks not clearly and closely related to host contracts. These instruments are required to be carried as derivative liabilities, at fair value. The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique for derivatives as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors. Items measured at fair value on a recurring basis include common stock warrants, and embedded derivatives related to the Company’s redeemable convertible preferred stock. During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The following fair value hierarchy table presents information about each major category of the Company's financial liabilities measured at fair value on a recurring basis: Quoted Prices in Active Markets Significant Other Significant for Identical Observable Inputs Unobservable Items (Level 1) (Level 2) Inputs (Level 3) Total December 31, 2015 Liabilities Series B redeemable convertible preferred stock $ - $ - $ 1,493,000 $ 1,493,000 Warrant liability - - 6,000 6,000 Total liabilities $ - $ - $ 1,499,000 $ 1,499,000 December 31, 2014 Liabilities Series B redeemable convertible preferred stock $ - $ - $ 12,320,000 $ 12,320,000 Warrant liability - - 5,826,000 5,826,000 Total liabilities $ - $ - $ 18,146,000 $ 18,146,000 There were no transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy for the years ended December 31, 2015 and 2014 . The following table sets forth a summary of changes in the fair value of the Company's Series B redeemable convertible preferred stock derivative and warrant liabilities, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy, wherein fair value is estimated using significant unobservable inputs: Series B Warrant Redeemable Liability Preferred Stock Balance, December 31, 2014 $ 5,826,000 $ 12,320,000 Issuances 4,210,000 - Exercises (677,000) - Conversions to common stock - (1,497,000) Warrants reclassified from liabilities to equity due to amendment of warrants (5,462,000) - Warrants reclassified from liabilities to equity due to increase in authorized shares (3,281,000) - Changes in estimated fair value (610,000) (9,330,000) Balance as of December 31, 2015 $ 6,000 $ 1,493,000 The fair value of the warrants on the date of issuance and on each re-measurement date for warrants classified as liabilities is estimated using the Monte Carlo valuation model. For this liability, the Company develops its own assumptions that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company’s common stock, stock price volatility, the contractual term of the warrants, risk–free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The following assumptions were used at December 31, 2015 and December 31, 2014 : December 31, 2015 December 31, 2014 Series (1) Series (1) June July December 2011 2011 2013 2013 2013 Volatility 112 % 155 % 155 % 155 % 151 % Expected term (years) 0.98 1.98 3.49 3.54 3.98 Risk-free interest rate 0.64 % 0.67 % 1.23 % 1.25 % 1.37 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % Exercise price $ 23.00 $ 23.00 $ 7.00 $ 7.00 $ 12.50 Common stock closing price $ 3.98 $ 10.50 $ 10.50 $ 10.50 $ 10.50 (1) See Note 11 – Warrants below for further description of the respective series of warrants. The warrant liability is recorded on the accompanying consolidated balance sheets and is marked-to-market at each reporting period, with the change in fair value recorded as a component of change in fair value of warrant liability on the Company’s statements of operations. The fair value of the Series B preferred stock derivative liability on each measurement date is estimated using the Monte Carlo valuation model. For this liability, the Company develops its own assumptions that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company’s common stock, stock price volatility, the expected term of the Series B Preferred, risk–free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the Series B preferred conversion liability is considered a Level 3 measurement. The following assumptions were used at December 31, 2015 and December 31, 2014 : December 31, 2015 December 31, 2014 Volatility 108 to 117 % 91 % Expected term (years), weighted average 0.50 to 2.50 1.25 Risk-free interest rate 0.49 to 1.19 % 0.36 % Dividend yield 0.00 % 0.00 % Exercise price $ 7.00 $ 7.00 Common stock closing price $ 3.98 $ 10.50 The Series B preferred stock derivative liability is recorded on the accompanying consolidated balance sheet and is marked-to-market each reporting period, with the change in fair value recorded as a component of change in fair value of Series B preferred stock derivative liability on the Company’s statements of operations.

Net (Loss) Income per Common Sh

Net (Loss) Income per Common Share	12 Months Ended
	Dec. 31, 2015
Net (Loss) Income per Common Share [Abstract]
Net (Loss) Income per Common Share	5 . Net (Loss) Income per Common Share The following table sets forth the computation of basic and diluted net (loss) income per share for the periods indicated (refer to Note 3 – Significant Accounting Policies for more information regarding the December 31, 2014 restatement): Year Ended December 31, 2015 Year Ended December 31, 2014 Net loss (Numerator) Shares (Denominator) Per share amount Net income (loss) (Numerator) Shares (Denominator) Per share amount Basic net (loss) income per common share: Net (loss) income and share amounts $ (516,000) 5,411,204 $ 23,109,000 3,746,639 Accretion of Series B redeemable convertible preferred stock (10,278,000) - (1,285,000) - Net (loss) income attributable to common stockholders (10,794,000) 5,411,204 21,824,000 3,746,639 Adjustment related to preferred stockholders' participation in the Company's undistributed earnings - - (6,067,000) - Basic (loss) income per share - restated for the year ended December 31, 2014 $ (10,794,000) 5,411,204 $ (1.99) $ 15,757,000 3,746,639 $ 4.21 Diluted net loss per common share: Accretion of Series B redeemable convertible preferred stock - - 1,285,000 - Adjustment related to preferred stockholders' participation in the Company's undistributed earnings - - 6,067,000 - Change in fair value of Series B stock derivative liability - - (27,760,000) - Dilutive shares related to Series B - - - 1,748,288 Change in fair value of warrant liability related to dilutive warrants - - (9,066,000) - Dilutive shares related to warrants - - - 391,803 Net loss attributable to common stockholders - diluted - restated for the year ended December 31, 2014 $ (10,794,000) 5,411,204 $ (1.99) $ (13,717,000) 5,886,730 $ (2.33) The following outstanding securities at December 31, 2015 and 2014 have been excluded from the computation of diluted weighted shares outstanding for the years ended December 31, 2015 and 2014 , as they would have been anti-dilutive: December 31, 2014 2015 (restated) Options 669,769 440,695 Series B redeemable convertible preferred stock 7,527,853 - Warrants 656,211 167,711

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property and Equipment [Abstract]
Property and Equipment	6 . Property and Equipment Property and equipment consist of the following: December 31, 2015 2014 Laboratory equipment $ 1,494,000 $ 1,454,000 Office and computer equipment 53,000 59,000 Leasehold improvements 188,000 185,000 Total gross fixed assets 1,735,000 1,698,000 Less: accumulated depreciation and amortization (604,000) (478,000) Property and equipment, net $ 1,131,000 $ 1,220,000 Depreciation expense totaled $ 299,000 and $ 127,000 for the years ended December 31, 2015 and 2014 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Income Taxes	7. Income Taxes Significant components of our deferred tax assets and liabilities are as follows: December 31, 2015 2014 Deferred tax assets/(liabilities) Net operating loss carry-forwards $ 65,425,000 $ 61,332,000 Research and orphan drug credit carry-forwards 5,181,000 3,855,000 Depreciation and amortization (3,000) (8,000) Stock options and other 479,000 1,381,000 Intangible assets (3,079,000) (3,155,000) Net deferred tax assets/(liabilities) 68,003,000 63,405,000 Valuation allowance for deferred tax assets (71,008,000) (66,483,000) Net deferred tax assets/(liabilities) $ (3,005,000) $ (3,078,000) At December 31, 2015 , the Company had U.S. gross net operating loss carry-forwards, or “NOLs”, of approximately $ 182.3 million , foreign NOLs of $ 8.5 million, $ 3.0 million of which was generated in 2015 an d domestic research tax credit carry-forwards of approximately $ 5.2 million. The carry-forwards may be further subject to the application of Section 382 of the Internal Revenue Code of 1986 or the “Code”, as discussed further below. The NOL carry-forwards will begin to expire in 2019 . The domestic research tax credit carry-forward will begin to expire in 2019 . The Company has provided a valuation allowance to offset the deferred tax assets due to the uncertainty of realizing the benefits of the net deferred tax asset. December 31, 2015 2014 Percent of pre-tax income: U.S. federal statutory income tax rate 34.0 % 34.0 % Warrant liability and preferred stock conversion liability 573.8 % (54.9) % Difference in foreign vs U.S. statutory rates (21.8) % - % Stock option forfeitures & expirations (138.2) % - % State taxes, net of federal benefit - % 3.7 % Non-deductible stock issuance costs (17.9) % - % R&D expenses associated with Australian research grants 27.8 % - % Effect of tax rate changes 12.4 % % All other (2.9) % 1.0 % Subtotal 467.2 % (16.2) % Change in valuation allowance (454.8) % 16.2 % Effective income tax rate 12.4 % 0.00 % The Company’s past sales and issuances of common and preferred stock have likely resulted in ownership changes as defined by Section 382 of the Code. The Company has not conducted a Section 382 study to date. It is possible that a future analysis may result in the conclusion that a substantial portion, or perhaps substantially all, of the NOLs and credits will expire due to the limitations of Sections 382 and 383 of the Code. As a result, the utilization of the NOLs and tax credits may be limited and a portion of the carry-forwards may expire unused. The Company does not have any material unrecognized tax benefits as of December 31, 2015 . The Company is subject to U.S. federal tax examinations by tax authorities for the years 1998 to 2015 due to the fact that NOLs exist going back to 1998 that may be utilized on a current or future year tax return. The Company has a policy of recognizing tax related interest and penalties as additional tax expense when incurred. During the years ended December 31, 2015 and 2014 , the Company did not recognize any interest and penalties.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating Leases Rent expense under operating leases was $ 192,000 and $ 314,000 in 2015 and 2014 , respectively. Future minimum lease payments, including termination fees, under noncancelable lease agreements as of December 31, 2015 , are as follows: Operating Lease 2016 $ 76,000 2017 39,000 2018 39,000 2019 5,000 Total minimum lease payments $ 159,000 The Company entered into an agreement with Virginia Biotechnology Research Partnership Authority for Richmond, Virginia laboratory space. This agreement has an expiration date of August 31, 2016, with the option to terminate the lease with 60 days’ notice. At December 31, 2015 , the Company’s minimum payment commitment for the Richmond laboratory space was $ 14,000. In May 2015, the Company entered into an agreement with Virginia Biotechnology Research Partnership Authority for Richmond, Virginia office space. This agreement has an expiration date of October 31, 2016, with the option to terminate the lease with 60 days’ notice. At December 31, 2015 , the Company’s minimum payment commitment for the Richmond office space is $ 18,000 . In June 2015, the Company entered into an agreement with Savills Studley, Inc. for San Diego, California office space. The agreement expired on June 30, 2015, and renews on a monthly basis, until terminated by the Company. At December 31, 2015 , the Company’s minimum payment commitment for the San Diego office space was $ 5,000 . In December 2014, the Company entered into an agreement with Nevis Limited and Charter Limited for laboratory space in Bedfordshire, United Kingdom with an initial expiration date of December 2017. The Company terminated this agreement effective December 31, 2015. In February 2014, the Company entered into an agreement with Avtotehna d.o.o. for manufacturing and research space in Ljubljana, Slovenia. The lease has a termination date of February 2019 , with extension provisions at the option of the Company, and a monthly payment is $ 3,244 . At December 31, 2015 , our minimum payment commitment for the Ljubljana space was $ 122,000 . In addition, the Company expended $ 185,000 in 2014 for leasehold improvements related to this facility. These costs are being amortized on a straight-line basis over the life of the related lease. The Company is subject to legal claims and actions related to the operations of its business. The Company does not expect the ultimate outcome of any such actions to have a material impact on its consolidated financial position or results of operations.

Collaborative and Other Agreeme

Collaborative and Other Agreements	12 Months Ended
	Dec. 31, 2015
Collaborative and Other Agreements [Abstract]
Collaborative and Other Agreements	9. Collaborative and Other Agreements In September 2015, the Company entered into a non-exclusive patent license agreement with Takara Bio Inc. (the Takara Agreement). Under this agreement Takara licensed certain patents related to AAV1 Vector gene delivery systems, for which the Company is an exclusive licensor with the University of Pennsylvania. The Company received a $ 40,000 non-refundable, up-front licensing payment which was recognized in revenue in 2015 and is entitled to receive royalties from Takara of 12.0 % of net license product sales and 6.0 % of service revenues associated with the licensed products. The agreement calls for minimum annual royalties of $ 15,000 beginning in 2015 which are payable in arrears in February on each anniversary thereafter. The minimum royalty amount was recognized in revenue in 2015. In addition, the Takara Agreement provides milestone fees to the Company of $ 30,000 of the first $ 1,000,000 of licensed product revenues by Takara and an additional $ 40,000 when cumulative net sales of the licensed product by Takara exceed $ 2,000,000. The Company is party to other sub-licensing agreements for its former gene delivery systems. The Company receives annual maintenance fees and royalties based on the activities of the licensees. The amounts are reported in revenues in accordance with our revenue recognition policy. In June 2013, the Company entered into a Collaborative Research and Development Agreement with the United States Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research. The Collaborative Research and Development Agreement is focused on developing and commercializing bacteriophage therapeutics to treat S. aureus infections. During the year ended December 31, 2015 , the Company recorded no payments under the Collaborative Research and Development Agreement. During the year ended December 31, 2014 , the Company paid Walter Reed Army Institute of Research $ 207,000 for services provided under the Collaborative Research and Development Agreement. This amount is included in research and development expense in 2014. In April 2013, the Company entered into a collaboration agreement with the University of Leicester to develop a phage therapy that targets and kills all toxin types of C. diffic i le. In August 2013, the Company entered into a collaboration agreement with both the University of Leicester and the University of Glasgow to carry out certain animal model development work. Under these agreements, which are referred to collectively as the Leicester Development Agreements, the Company provides payments to the University of Leicester to carry out in vitro and to the University of Glasgow to carry out animal model development work on the University of Leicester’s development of a bacteriophage therapeutic to resolve C. difficile infections. The Company licensed related patents, materials and know-how from the University of Leicester. Under the Leicester Development Agreements, the University of Leicester will provide the bacteriophage and act as overall project coordinator for the development work. All rights, title and interest to any intellectual property developed under the Leicester Development Agreements belong to the Company. Under the Leicester License Agreement, the Company has exclusive rights to certain background intellectual property of the University of Leicester, for which it will pay the University of Leicester royalties based on product sales and make certain milestone payments based on product development. In November 2015, the Company renewed this collaboration, effective as of November 12, 2015. This agreement expires November 12, 2018 . During the year ended December 31, 2015 , the Company recorded $ 265,000 in expenses to the University of Leicester under the Leicester Development Agreements, with cash payments totaling $ 290,000 . During the year ended December 31, 2014 , the Company recorded $ 232,000 in expenses to the University of Leicester under the Leicester Development Agreements, with cash payments totaling $ 182,000 . During the year ended year ended December 31, 2015 , the Company paid and expensed amounts to the University of Glasgow under the Leicester Development Agreements of $ 61,000 . During the year ended December 31, 2014 , the Company paid and expensed amounts to the University of Glasgow under the Leicester Development Agreements of $ 184,000 . In March 2013, the Company entered into an Exclusive Channel Collaboration Agreement with Intrexon Corporation. This agreement allows the Company to utilize Intrexon’s synthetic biology platform for the identification, development and production of bacteriophage-containing human therapeutics. The Company paid a one-time technology access fee in 2013 to Intrexon of $ 3,000,000 in common stock. Pursuant to the agreement, the Company is required to pay Intrexon, in cash or stock to be valued based on the market price of our common stock , milestone fees of $ 2,500,000 for the initiation and commencement of the first Phase 2 trial and $ 5,000,000 upon the first regulatory approval of any product in any major market country. With regard to each product sold by the Company, the Company is required to pay, in cash, tiered royalties on a quarterly basis based on net sales of AmpliPhi Products, calculated on a product-by-product basis. No milestones have been met and no milestone payments have been paid or accrued for through December 31, 2015 . The Exclusive Channel Collaboration is effective until terminated by either Intrexon or the Company . Intrexon may terminate the Exclusive Channel Collaboration if the Company fail s to use diligent efforts to develop and commercialize AmpliPhi Product candidates or if the Company elect s not to pursue the development of an AmpliPhi Program identified by Intrexon that is a “Superior Therapy” as defined in the Exclusive Channel Collaboration. The Company has the right to terminate the Exclusive Channel Collaboration upon 90 days’ written notice to Intrexon at any time. Both the Company and Intrexon have the right to terminate the Exclusive Channel Collaboration upon written notice to the other party if the other party commits a material breach of the agreement and fails to cure such breach within 60 days following written notice. During the year ended December 31, 2015 , the Company recorded $ 178,000 , in expenses under the Exclusive Channel Collaboration Agreement, with cash payments totaling $ 125,000 . During the year ended December 31, 2014 , the Company recorded $ 862,000 , in expenses under the Exclusive Channel Collaboration Agreement, with cash payments totaling $ 941,000 .

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2015
Redeemable Convertible Preferred Stock [Abstract]
Redeemable Convertible Preferred Stock	10. Redeemable Convertible Preferred Stock On June 13, 2013, the Company’s Board of Directors approved a resolution designating 10,000,000 shares of Preferred Stock as Series B redeemable convertible preferred stock (Series B) with an initial stated value of $ 1.40 and par value of $ 0.01 . Each Series B share is convertible into 0.20 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock into which such Series B share may be converted. These Series B shares may be converted to common stock by the holder of the shares at any time. The Series B shares may be automatically converted into common stock upon the election of the holders of at least two-thirds of the outstanding Series B shares. In addition, pursuant to the Company’s Articles of Incorporation, the Series B shares are automatically convertible into common stock upon an underwritten initial public offering by the Company, with aggregate proceeds to the Company of at least $ 7.0 million and a price per share to the public of at least the Series B stated value of $ 1.40 per share upon the closing of which the shares of common stock of the Company are listed for trading on a major national stock exchange. Holders of the Series B shares are entitled to receive cumulative, cash dividends at the rate of 10 % of the Series B stated value. Such dividends accrue from day-to-day commencing on the original issue date, whether or not earned or declared by the Board of Directors, and are compounded annually. No dividends have been declared or paid through December 31, 2015 . At any time on or after June 26, 2018, the holders of at least two-thirds of the outstanding Series B shares may require the Company to redeem all of the outstanding Series B shares for an amount equal to the original issue price per share plus any accrued and unpaid dividends. Holders of the Series B are entitled to a liquidation preference in an amount equal to the Series B stated value of $ 1.40 per share plus all accrued and unpaid dividends in the event of a liquidation, dissolution, or winding-up of the Company, or in the event the Company merges with or is acquired by another entity. As noted in Note 2 – Liquidity , the Company has a disagreement with one of its principal stockholders, Third Security, LLC, regarding the interpretation of the Company’s Amended and Restated Articles of Incorporation. The disagreement relates to whether it is technically possible for the Company to satisfy the requirements for automatic conversion of the Company’s outstanding shares of Series B Redeemable Convertible Preferred Stock (Series B Preferred) pursuant to an underwritten public offering. In connection with the private placement of Series B, the Company recorded a liability for an embedded derivative that required bifurcation under the applicable accounting guidance. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with specified anti-dilution adjustments for certain financing transactions involving the issuance of securities at a price below a minimum non-diluting issuance price of $ 7.00 per share. The following table summarizes the conversions of Series B shares to common stock pursuant to Series B stockholder elections during the year ended December 31, 2015 : Amount Reclassified Series B Common from Liability Conversion Shares Stock into Stockholders' Date Converted Issued Equity (1) April 8, 2015 107,100 21,420 $ 219,000 May 4, 2015 23,587 4,717 36,000 May 11, 2015 250,000 50,000 381,000 July 16, 2015 262,500 52,500 318,000 August 13, 2015 500,000 100,000 543,000 Totals 1,143,187 228,637 $ 1,497,000 (1) Not inclusive of $9 ,000 reclassified from Series B redeemable convertible preferred stock and liabilities for dividends payable of $368,000 upon conversion of these shares. The Company re-measured the fair value of the derivative feature and recorded a gain of $ 9,330,000 for the year ended December 31, 2015 to adjust the liability associated with the conversion feature to its estimated fair value of $ 1,493,000 as of December 31, 2015 . At December 31, 2015 , the Company reclassified $ 8,971,000 from additional paid-in capital to Series B redeemable convertible preferred stock to adjust the Series B redeemable convertible preferred stock to its redemption value at that date. At December 31, 2015 , the Company recorded dividends payable of $ 368,000 to former holders of preferred stock, which are classified as current liabilities on the Company’s Balance Sheet at that date .

Warrants

Warrants	12 Months Ended
	Dec. 31, 2015
Warrants [Abstract]
Warrants	11 . Warrants In connection with the March 16, 2015 private placement of 1,575,758 shares of the Company’s common stock at a price per share of $ 8.25 , the Company issued warrants (Series March 2015) to purchase an aggregate of 393,939 shares of common stock at an exercise price of $ 10.75 per share to the purchasers of the common stock. In addition, the Company issued warrants to purchase an aggregate of 94,545 shares of common stock at an exercise price of $ 10.75 per share to the placement agents as a cost of issuing the common stock . These warrants expire in March 2020 and provided for a contingent cash payment of $ 2.5 million in liquidated damages to the holders of the warrants in the event the Company failed to either (i) increase the number of shares of common stock the Company is authorized to issue or (ii) effect a reverse split of the common stock, in either event sufficient to permit the exercise in full of the Warrants in accordance with their terms. Due to these provisions, the Company accounted for these warrants as liability instruments prior to the third quarter of 2015 , after these conditions were met . The Company measured the fair value of these warrants on March 16, 2015 and recorded an initial warrant liability of $ 4,210,000 , of which $ 3,396,000 represented the initial fair value of the warrants issued to investors and $ 814,000 as the initial fair value of the warrants issued to the placement agents. The Company recorded other expenses of $ 213,000 for the year ended December 31, 2015 representing a portion of the initial fair value of warrants issued to the placement agents attributable to the initial fair value of the warrants issued. In connection with the December 2013 private placement of 1,440,140 shares of the Company’s common stock at a price per share of $ 12.50 , the Company issued warrants (Series December 2013) to purchase an aggregate of 86,408 shares of common stock at an exercise price of $ 12.50 per share to the placement agents. These warrants, which expire December 2018 , contain specified anti-dilution adjustment provisions for certain financing transactions involving the issuance of securities below a specified price and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liability instruments. As a result of the March 16, 2015 private placement of common stock at a price of $ 8.25 per share, the anti-dilution adjustment provisions of these warrants resulted in an adjustment to their exercise price to $ 8.25 as of March 16, 2015. In connection with the private placement of Series B, which occurred through two closings on June 26, 2013 and July 15, 2013, the Company issued warrants (Series June 2013 and Series July 2013, respectively) to purchase an aggregate of 600,805 shares of common stock at an exercise price of $ 7.00 per share. These warrants, which expire in June 2018 and in July 2018 , respectively, contain anti-dilution adjustment provisions and contain net settlement provisions. Due to these provisions, the Company accounts for these warrants as liability instruments. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded initial warrant liabilities of $ 4,285,000 and $ 674,000 , respectively, as part of the private placement proceeds and expensed $ 759,000 for warrants issued to the placement agent. In January 2011, we completed the acquisition of Biocontrol Limited, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage therapy programs using funding from the sale of our legacy gene therapy assets. On December 22, 2011, in connection with our acquisition of Biocontrol, the Company issued warrants (Series 2011) to purchase up to 27,103 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $ 23.00 per share. As the terms of these warrants require that they be settled in registered shares of common stock, the Company accounts for these warrants as liability instruments. The Company estimates the fair values of all warrants accounted for as liability instruments using a Monte Carlo valuation model. From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants (Series 2013 Convertible Notes Warrants) to purchase up to 140,608 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $ 7.00 per share. The Company classifies these warrants as equity instruments. On April 1, 2015, 52,120 warrants , issued on June 26, 2013, were exercised, resulting in the issuance of 52,120 shares of common stock and $ 630,000 being reclassified from the warrant liability account and into stockholders’ equity, based on the fair value of the warrants on the exercise date. On April 29, 2015, 4,52 5 warrants, issued on June 26, 2013, were exercised, resulting in the issuance of 4,52 5 shares of common stock and $ 46,000 was reclassified from the warrant liability account and into stockholders’ equity, based on the fair value of the warrants on the exercise date. On May 8, 2015, the Company, upon approval of more than two-thirds of the holders of the 2013 warrants issued on June 26, 2013, July 15, 2013 and December 23, 2013, amended these warrants to remove certain anti-dilution adjustment provisions. As a result of this amendment, all outstanding warrants from those issuance dates were reclassified as equity instruments resulting in the reclassification of $ 5,462,000 from the warrant liability to stockholders’ equity, reflecting the fair value of these warrants on the amendment date. On August 3, 2015, the stockholders of the Company approved a 1-for-50 reverse stock split of the Company’s common stock and increased the number of authorized shares of common stock to 670,000,000 . As a result, the warrants issued in conjunction with the March 2015 private placement of common stock were reclassified from liability instruments to equity instruments. Accordingly, $ 3,281,000 was reclassified from warrant liability to stockholders’ equity, reflecting the fair value of these warrants on the effective date of the reverse split, and the accrued fair value of liquidated damages in the amount of $ 120,000 was recorded as other income within the caption “Other expense” on the Company’s statement of operations. The Company re-measured the fair value of the warrant liability and recorded a gain of $ 610,000 for the year ended December 31, 2015 , reflecting a decrease in the liability associated with the warrants at their estimated fair value, which totaled $ 6,000 as of December 31, 2015 . All exercise prices and share amounts of warrants are after giving consideration to the 1-for-50 reverse split of the Company’s common stock which was effective August 7, 2015. The following table provides a summary of warrants outstanding, issued or exercised for the year ended December 31, 2015 . Also included is the average exercise price per share and the aggregate proceeds to the Company if exercised as of December 31, 2015 . Series June 2013 and July 2013 March 2015 Series B Warrants December 2013 2013 Convertible Notes 2011 Totals Weighted Average Exercise Exercise Exercise Exercise Exercise Exercise Shares Price Shares Price Shares Price Shares Price Shares Price Shares Price Balance, December 31, 2014 - $ - 523,691 $ 7.00 86,408 $ 12.50 140,608 $ 7.00 27,103 $ 23.00 777,810 $ 8.00 Issuances 488,484 10.75 - - - - - - - - 488,484 10.75 Exercises - - (56,645) 7.00 - - - - - - (56,645) 7.00 Balance, December 31, 2015 488,484 $ 10.75 467,046 $ 7.00 86,408 $ 8.25 140,608 $ 7.00 27,103 $ 23.00 1,209,649 $ 8.96 Aggregate proceeds if exercised $ 5,251,203 $ 3,269,322 $ 712,866 $ 984,254 $ 623,369 $ 10,838,453

Stock Incentive Plan Compensati

Stock Incentive Plan Compensation	12 Months Ended
	Dec. 31, 2015
Stock Incentive Plan Compensation [Abstract]
Stock Incentive Plan Compensation	12. Stock Incentive Plan Compensation The Company’s 2013 Stock Incentive Plan (Stock Incentive Plan) provides for the issuance of incentive awards, or awards, in the form of non-qualified and incentive stock options, stock appreciation rights, stock grants and restricted stock units. The awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. Stock options expire no later than ten years from the date of grant and generally vest and typically become exercisable over a four-year period following the date of grant. Every non-employee member of the Company’s Board of Directors may also receive an annual non-qualified stock option or restricted stock unit grant. Upon the exercise of stock options, the Company issues the resulting shares from shares reserved for issuance under the Stock Incentive Plan. The Company account s for stock options and restricted stock units related to its stock incentive p lans under the provisions of ASC 718, which requires the recognition of the fair value of stock-based compensation. The fair value of stock options and restricted stock units was estimated using a Black-Scholes option valuation model. This model requires the input of subjective assumptions in implementing ASC 718, including expected dividend, expected life, expected volatility and forfeiture rate of each award, as well as the prevailing risk-free interest rate and the fair value of the underlying common stock on the date of grant. The fair value of equity-based awards is amortized over the vesting period of the award, and the Company has elected to use the straight-line method of amortization. The assumptions used in the Black-Scholes option valuation model for the years ended December 31, 2015 and 2014 are set forth below. The following are the assumptions for the periods in which we granted stock options:  Expected Dividend : The Company does not anticipate paying any dividends on its common stock.  Expected Life : The expected life represents the period that the Company expect s its stock-based awards to be outstanding. For awards in fiscal 2014, the Company’s expected life was based on historical experience . During fiscal 2015, the Company’s expected life assumption was based on the simplified method set forth in the SEC Staff Accounting Bulletin 110, as the Company determined the use of this method provides a more reasonable estimate of expected life. The Company’s estimation of the expected life for stock options granted to parties other than employees or directors is the contractual term of the option award.  Expected Volatility : The Company’s expected volatility represents the weighted average historical volatility of the shares of its common stock for the expected life of the stock options .  Risk-Free Interest Rate : The Company base s the risk-free interest rate used on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Where the expected term of its stock-based awards does not correspond with the terms for which interest rates are quoted, the Company perform s a straight-line interpolation to determine the rate from the available term maturities.  Forfeiture Rate : The Company appl ies an estimated forfeiture rate that is derived from historical forfeited shares. If the actual number of forfeitures differs from our estimates, the Company may record additional adjustments to compensation expense in future periods. The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock option grants were as follows: Years Ended December 31, 2015 2014 Risk-free interest rate 1.55 to 1.78 % 1.30 % Expected volatility 139.0 % 160.9 % Expected term (in years) 6.0 to 10.0 4.0 Expected dividend yield 0.0 % 0.0 % Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. The estimated grant-date fair value of the Company’s stock-based awards is amortized ratably over the awards’ service periods. Stock-based compensation expense recognized was as follows: Year Ended December 31, 2015 2014 Research and development $ 122,000 $ 143,000 General and administrative 357,000 632,000 Severance charge 4,000 1,161,000 Total stock-based compensation expense $ 483,000 $ 1,936,000 (1) The severance charge component of stock incentive plan compensation relates to accelerated vesting of stock options held by the Company’s former Chief Executive Officer and a former executive per the terms of their employment agreements. The following table summarizes stock option activity for the year ended December 31, 2015 : Options Outstanding Average Weighted Remaining Shares Average Contractual Available Exercise Term Intrinsic For Grant Shares Price (Years) Value Balance, December 31, 2014 785,000 440,695 $ 9.37 8.18 $ 640,837 Increase in authorized shares 520,000 - - - - Granted (596,569) 596,569 8.47 - - Exercised - (214,815) 8.00 - (383,994) Forfeited 4,375 (4,812) 13.64 - - Expired 10,625 (147,868) 10.71 - - Balance, December 31, 2015 723,431 669,769 $ 8.68 9.29 $ - Vested or expected to vest at December 31, 2015 552,340 $ 10.03 9.21 $ - Exercisable at December 31, 2015 67,084 $ 10.03 6.71 $ - The intrinsic value of options exercisable as of December 31, 2015 was $0.0 million, based on the Company’s closing stock price of $ 3.98 per share and a weighted average exercise price of $ 10.03 per share. The Company uses the Black-Scholes option-pricing model to estimate the fair value of standard stock options at the grant date. The Black-Scholes model requires the Company to make certain estimates and assumptions, including estimating the fair value of the Company’s common stock, assumptions related to the expected price volatility of the Company’s common stock, the period during which the options will be outstanding, the rate of return on risk-free investments and the expected dividend yield for the Company’s common stock. The Company uses Monte Carlo valuation models to estimate the fair value of certain stock options with market-based vesting requirements. This method of option pricing involves the use of inputs such as the market value of the Company’s common stock, stock price volatility, the period during which the options will be outstanding, the rate of return on risk-free investments, expected dividend yield for the Company’s stock, and certain estimates of future value of the Company’s common stock. During 2015, the Company issued 596,569 common stock options to its executives , board members , and consultants with a weighted average exercise price $ 8.47 per share. Included in this amount were 399,716 stock options, with an exercise price of $ 9.45 , awarded to its Chief Executive Officer, pursuant to his employment agreement dated April 24, 2015. As of December 31, 2015 , there was $ 3.6 million of total unrecognized compensation expense related to unvested stock options that will be recognized over the weighted average remaining period of 6.71 years. Shares Reserved For Further Issuance As of December 31, 2015 , the Company had reserved shares of its common stock for future issuance as follows: Shares Reserved Stock options outstanding 669,769 Available for future grants under the Stock Incentive Plan 723,431 Warrants 1,209,649 Total shares reserved 2,602,849

Employee Retirement Plan

Employee Retirement Plan	12 Months Ended
	Dec. 31, 2015
Employee Retirement Plan [Abstract]
Employee Retirement Plan	13. Employee Retirement Plan The Company sponsors an employee retirement plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. All of the Company’s employees who meet minimum eligibility requirements are eligible to participate in the plan. Matching contributions to the 401(k) plan are made at the discretion of the Company’s Board of Directors. The Company suspended matching contributions effective January 1, 2009 and accordingly no matches were approved in 2014 or 2015 .

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2015
Related Parties [Abstract]
Related Parties	14. Related Parties As of December 31, 2015 and December 31, 2014 , $ 56,000 and $ 3,000 , respectively, of current liabilities were due to related parties. Randal J. Kirk, the father of Julian P. Kirk, a member of our board of directors, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Randal J. Kirk is also deemed a holder of more than five percent of the shares of our common stock, as described in the section entitled “Security Ownership of Certain Beneficial Owners and Management” in our definit ive proxy statement for the 2015 annual meeting of stockholders. In March 2013, the Company entered into an Exclusive Channel Collaboration Agreement with Intrexon Corporation. This agreement allows the Company to utilize Intrexon’s synthetic biology platform for the identification, development and production of bacteriophage-containing human therapeutics. The Company paid a one-time technology access fee in 2013 to Intrexon of $ 3,000,000 in common stock. The Company is required to pay Intrexon, in cash or stock, milestone fees for the initiation and commencement of the first Phase 2 trial of $ 2,500,000 and $ 5,000,000 upon the first regulatory approval of any product in any major market country. With regard to each product sold by the Company, the Company will pay, in cash, tiered royalties on a quarterly basis based on net sales of AmpliPhi Products, calculated on a product-by-product basis. No milestones have been met and no milestone payments have been paid to Intrexon through December 31, 2015 . The Company paid $ 125,000 and $ 941,000 to Intrexon in 2015 and 2014 , respectively, for technical services rendered under the agreement.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity (Deficit) [Abstract]
Stockholders' Equity (Deficit)	15. Stockholders’ Equity On March 16, 2015, the Company issued and sold 1,575,758 shares of common stock in a private placement at a price of $ 8.25 per share, for aggregate proceeds of $ 13.0 million. In conjunction with this private placement, the Company issued warrants to purchase an aggregate of 393,9 39 shares of common stock at an exercise price of $ 10.75 per share to the purchasers of the common stock. The Company paid $ 833,000 in fees to its placement agents, along with the issuance of warrants to purchase an aggregate of 94,54 5 shares of common stock at an exercise price of $ 10.75 per share. The Company initially valued these warrants as liability instruments and recorded a liability of $ 4,210,000 as of March 16, 2015. In the first quarter of 2015, the Company recorded $ 213,000 of other expenses representing the portion of the initial warrant value of the placement agent warrants related to the initial fair value of the warrants issued to the purchasers of the common stock. The remainder of the initial fair value of the warrants of $ 3,996 ,000 was treated as a reduction of additional paid-in-capital. In addition, $ 218,000 of the fees paid to its placement agent were expensed as other expenses in the year ended December 31, 2015 as they also represented issuance costs related to the initial fair value of the warrants issued to the purchasers of the common stock. The derived value associated with these warrants was reclassified from liabilities to equity in the third quarter of 2015 in connection with the increase in the authorized number of common shares.

Severance Charge

Severance Charge	12 Months Ended
	Dec. 31, 2015
Severance Charge [Abstract]
Severance Charge	16. Severance Charge In 2015, the Company recorded a severance charge of $ 289,000 related to the departure of an executive, which included severance period compensation and benefits and stock-based compensation related to the accelerated vesting of stock options. The Company incurred a severance charge of $ 1,864,000 in 2014 related to the departure of its Chief Executive Officer in September 2014. The charge consisted of severance-period cash compensation and benefits and non-cash stock-based compensation expense related to the accelerated vesting of stock options, pursuant to his employment agreement with the Company. The severance accrual related to cash compensation and benefits as of December 31, 2014 and December 31, 2015 is as follows: Accrued severance, December 31, 2014 $ 555,000 Cash payments in 2015 (529,000) Additions in 2015 282,000 Accrued severance, December 31, 2015 $ 308,000

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Quarterly Financial Data	17. Quarterly Financial Data (Unaudited) Subsequent to the issuance of the consolidated financial statements for the period ended September 30, 2015, the Company identified errors as described in Note 3 – Significant Accounting Policies that affected the interim consolidated financial statements for the three and six months ended June 30, 2014, three and nine months ended September 30, 2014 and the three months ended June 30, 2015. Accordingly, the previously issued consolidated financial statements for the aforementioned periods have been restated to correct for these errors below and summarized in the tables that follow. The Company corrected its calculation of basic and diluted income (loss) per share of common stock for the changes to net income (loss) and errors in the calculation of the weighted average diluted shares. The following tables present the impact of these corrections: Three Months Ended June 30, 2015 Three Months Ended September 30, 2014 Nine Months Ended September 30, 2014 Three Months Ended June 30, 2014 Six Months Ended June 30, 2014 Basic income per share - as originally reported $ 1.58 $ 5.58 $ 6.19 $ 3.69 $ 0.53 Difference in basic income per share (0.31) (1.71) (1.82) (1.13) (0.06) Basic income per share - restated $ 1.27 $ 3.87 $ 4.37 $ 2.56 $ 0.47 Diluted income per share - as originally reported $ 1.17 $ 3.30 $ 3.53 $ 2.09 $ 0.30 Difference in diluted loss per share (1.50) (4.16) (5.49) (2.72) (1.36) Diluted loss per share - restated $ (0.33) $ (0.86) $ (1.96) $ (0.63) $ (1.06) Numerator As originally reported $ 8,941,000 $ 20,884,000 $ 22,818,000 $ 13,555,000 $ 1,934,000 Correction - adjustment related to preferred stockholders' participation in the Company's undistributed earnings (1,716,000) (6,391,000) (6,703,000) (4,166,000) (202,000) Numerator for use in basic income per share, as restated $ 7,225,000 $ 14,493,000 $ 16,115,000 $ 9,389,000 $ 1,732,000 Correction - adjustment related to warrants and preferred stock (9,707,000) (19,459,000) (27,624,000) (13,131,000) (8,009,000) Numerator for use in diluted income (loss) per share, as restated $ (2,482,000) $ (4,966,000) $ (11,509,000) $ (3,742,000) $ (6,277,000) Denominator As originally reported 7,658,556 6,319,802 6,472,093 6,497,619 6,514,181 Less antidilutive shares previously incorrectly included in denominator (113,069) (532,898) (587,830) (591,594) (585,363) Denominator for use in diluted loss per share, as restated 7,545,487 5,786,904 5,884,263 5,906,025 5,928,818 T he denominator for the basic income per share calculation remains unchanged from the amount previously reported. The following table summarizes the outstanding securities that have been excluded from the computation of diluted weighted shares outstanding. Three Months Ended June 30, 2015 Three Months Ended September 30, 2014 Nine Months Ended September 30, 2014 Three Months Ended June 30, 2014 Six Months Ended June 30, 2014 Options, as restated 360,635 436,632 436,632 499,380 499,380 Warrants, as restated 167,711 167,711 140,608 140,608 140,608 Shares in escrow, as restated - 240,000 240,000 240,000 240,000 Total 528,346 844,343 817,240 879,988 879,988 The following tables summarize the unaudited quarterly statements of operations for the Company for 2015 and 2014 . The tables include all necessary adjustments, consisting only of normal recurring adjustments necessary in the opinion of management for a fair statement of the results for interim periods. 2015 Three-Months Ended Three-Months Ended Three-Months Ended Three-Months Ended March 31, June 30, September 30, December 31, Revenue $ 102,000 $ 102,000 $ 143,000 $ 128,000 Total operating expenses 2,369,000 2,694,000 2,571,000 3,068,000 Loss from operations (2,267,000) (2,592,000) (2,428,000) (2,940,000) Other income (expense), net (12,226,000) 13,361,000 7,867,000 636,000 Income tax benefit - - - 73,000 Net (loss) income (14,493,000) 10,769,000 5,439,000 (2,231,000) Accretion of Series B redeemable convertible preferred stock (338,000) (1,828,000) (7,163,000) (949,000) Net (loss) income attributable to common stockholders (14,831,000) 8,941,000 (1,724,000) (3,180,000) Net (loss) income per share of common stock – basic - restated for the three months ended June 30, 2015 (3.49) 1.27 (0.30) (0.54) Net loss per share of common stock – diluted - restated for the three months ended June 30, 2015 (3.49) (0.33) (0.30) (0.54) 2014 Three-Months Ended Three-Months Ended Three-Months Ended Three-Months Ended March 31, June 30, September 30, December 31, (1) Revenue $ 104,000 $ 101,000 $ 103,000 $ 101,000 Total operating expenses 2,638,000 3,849,000 5,334,000 2,698,000 Loss from operations (2,534,000) (3,748,000) (5,231,000) (2,597,000) Other income (expense), net (8,773,000) 17,621,000 26,438,000 1,933,000 Income tax benefit - - - - Net (loss) income (11,307,000) 13,873,000 21,207,000 (664,000) Accretion of Series B redeemable convertible preferred stock (314,000) (318,000) (323,000) (330,000) Net (loss) income attributable to common stockholders (11,621,000) 13,555,000 20,884,000 (994,000) Net (loss) income per share of common stock – basic - restated for the three months ended June 30, 2014 and September 30, 2014 (3.18) 2.56 3.87 (0.25) Net loss per share of common stock – diluted - restated for the three months ended June 30, 2014 and September 30, 2014 (3.18) (0.63) (0.86) (0.44) (1) Not previously reported.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events In January 2016, the Company entered into an Asset Purchase A greement with Novolytics Ltd. ( the “ Novolytics Purchase Agreement”), to purchase certain tangible and intangible assets. Pursuant to the Novolytics Purchase Agreement, the Company received all rights, title and interest held by Novolytics to three families of patents. In consideration for the assets acquired , the Company paid cash consideration of $ 146,000 and we issued warrants to purchase up to an aggregate of 170,000 shares of our common stock. The warrants have an exercise price of $ 12.00 per share and contain certain registration rights. One half of the shares subject to the warrant become exercisable on the date that is the earlier of 30 days following the expiration of the lock-up period for our next public offering, or December 31, 2016. The remaining shares subject to the warrant become exercisable 60 days thereafter. The warrants will expire upon the later of the close of business of the 24 -month anniversary of the date the warrants first become exercisable, as described in the preceding sentence, or the 24-month anniversary of the initial effectiveness of a registration statement covering the exercise shares. The fair value of the consideration granted and the allocation to the assets acquired will be determined and reported in the first quarter of 2016.

Liquidity (Policies)

Liquidity (Policies)	12 Months Ended
	Dec. 31, 2015
Organization and Description of the Business [Abstract]
Liquidity and Going Concern	The Company has prepared the se consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception, has negative operating cash flows and has an accumulated deficit of $362.5 million as of December 31, 2015 , $ 47.0 million of which has been accumulated since January of 2011, when the Company began its focus on bacteriophage development. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. As of December 31, 2015 , the Company had cash and cash equivalents of $ 9.4 million. Management believes that our existing resources will be sufficient to fund our planned operations through the third quarter of 2016. The Company’s ability to raise additional funds will depend, in part, on the status of its product development activities and other business operations, as well as factors related to financial, economic, and market conditions, many of which are beyond its control. In addition, the Company has a disagreement with one of its principal stockholders, Third Security, LLC, regarding the interpretation of the Company’s Amended and Restated Articles of Incorporation. The disagreement relates to whether it is technically possible for the Company to satisfy the requirements for automatic conversion of the Company’s outstanding shares of Series B Redeemable Convertible Preferred Stock (Series B Preferred) pursuant to an underwritten public offering (a Qualified Public Offering). In the fourth quarter of 2015, Third Security informed the Company that, under its interpretation of the Amended and Restated Articles of Incorporation, the Qualified Public Offering conditions set forth in Article 4 of the Amended and Restated Articles of Incorporation can never be satisfied because the Company’s stock is publicly traded on the NYSE MKT, and that the only way all outstanding Series B Preferred can be converted into common stock is by obtaining the requisite consent of the Series B Preferred stockholders. The Company disagrees with Third Security’s interpretation. The Amended and Restated Articles of Incorporation also contain various other ambiguities, such as in the provisions relating to the conversion rate for converting Series B Preferred into common stock and the stated value of the Series B Preferred following the Company’s 50:1 reverse split of its common stock in August 2015. The stated value of the Series B Preferred affects other provisions of the Amended and Restated Articles of Incorporation, including the anti-dilution rights for the Series B Preferred as well as the minimum public offering price per share necessary for a public offering to satisfy one of the Qualified Public Offering conditions. These ambiguities, as well as Third Security’s interpretation of the Qualified Public Offering conditions, create uncertainty around the Company’s capital structure, which may adversely affect the Company’s ability to raise capital. The Company cannot be certain that sufficient funds will be available to it when required or on acceptable terms, if at all. If adequate funds are not available on a timely basis or on acceptable terms, the Company may be required to significantly reduce or refocus its operations or to obtain funds through additional arrangements that may require the Company to relinquish rights to certain of its products, technologies or potential markets, any of which could delay or require that it curtail or eliminate some or all of its development programs or otherwise have a material adverse effect on the business, financial condition and results of operations. This uncertainty around the Company’s ability to secure additional financing creates substantial doubt about its ability to continue as a going concern.

Significant Accounting Polici26

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol Limited, Ampliphi d.o.o., and AmpliPhi Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated.
Restatement of Prior Period Financial Statements	Restatement of Prior Period Financial Statements The Company has determined that a restatement is required to the previously reported basic and diluted income ( loss ) per share for the year ended December 31, 2014 , three and six months ended June 30, 2014, three and nine months ended September 30, 2014 and three months ended June 30, 2015 . The correction has no impact on the Company’s consolidated balance sheets, statement of operations, or the consolidated statement of cash flows as previously reported for the aforementioned periods . Furthermore, the correction does not impact any other previously reported periods in 2014 and 2015 . The Company has not amended its previously-filed Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q for the periods affected by the restatement. The financial information related to basic and diluted income (loss) per share that has been previously filed or otherwise reported for these periods is superseded by the information in this Form 10-K, and the financial statements and related financial information contained in such previously-filed reports should no longer be relied upon. No other changes were made to these previously filed reports other than those disclosures related to basic and diluted income (loss) per share. The calculation of basic income (loss) per share requires consideration of the fact that the outstanding shares of the Company’s Series B redeemable convertible preferred stock , in certain limited circumstances, have the right to receive additional dividends beyond their accruing dividends and are consequently participating securities. Therefore, consideration of this component of the preferred stock terms is included in computing basic earnings per share pursuant to the two-class method. The Company failed to make such adjustments to the basic income (loss) per share calculations for the prior periods discussed above. The calculation of diluted income ( loss ) per share requires that , to the extent such securities are dilutive to income/loss per share for the period, an adjustment to net income ( loss ) used in the calculation is required to remove the change in fair value of the liability classified warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares. Similarly, the diluted income ( loss ) per share calculation also requires an adjustment to net loss used in the calculation to remove the change in fair value of the Series B redeemable convertible prefer red stock embedded derivative ( if the Series B redeemable convertible preferred stock is dilutive), including any applicable accretion, and an adjustment to the denominator is required to reflect the related dilutive securities. The Company failed to make such adjustments to the diluted income (loss) per share calculations for the prior periods discussed above. The table below illustrates a reconciliation of the components of the numerator and denominator included in the calculations of basic and diluted income (loss) per share and the impact of the correction of the error on the basic and diluted income (loss) per share amounts. Year Ended December 31, 2014 Basic income per share - as originally reported $ 5.82 Difference in basic income per share (1.61) Basic income per share - restated $ 4.21 Diluted loss per share - as originally reported $ 3.37 Difference in diluted loss per share (5.70) Diluted loss per share - restated $ (2.33) Numerator As originally reported $ 21,824,000 Correction - adjustment related to preferred stockholders' participation in the Company's undistributed earnings (6,067,000) Numerator for use in basic income per share, as restated 15,757,000 Correction - adjustments related to warrants and preferred stock (29,474,000) Numerator for use in diluted loss per share, as restated $ (13,717,000) Denominator As originally reported 6,472,093 Less antidilutive shares previously incorrectly included in denominator (585,363) Denominator for use in diluted loss per share, as restated 5,886,730 The denominator for the basic income per share calculation remains unchanged from the amount previously reported. The tables in Note 17 – Quarterly Financial Data illustrate a reconciliation of the components of the numerator and denominator included in the calculations of basic and diluted income ( loss ) per share for the three and six months ended June 30, 2014, three and nine months ended September 30, 2014 and the three months ended June 30, 2015 .
Reverse Stock Split Policy	Reverse Stock Split On August 3, 2015, the Company filed Articles of Amendment to Amended and Restated Articles of Incorporation with the Secretary of State of the State of Washington that effected a 1-for-50 (1: 50 ) reverse stock split of its common stock, par value $0.01 per share , effective August 7, 2015. On August 3, 2015, the Company also increased its authorized common stock, from 445,000,000 to 670,000,000 shares. The par value of its common stock was unchanged at $ 0.01 per share, post-split. All warrant, stock option, and per share information in the consolidated financial statements gives retroactive effect to the 1-for-50 reverse stock split that was effected on August 7, 2015.
Use of Estimates	Use of Estimates Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: the determination of the fair value of stock-based awards, the fair value of liability-classified preferred stock derivatives, the fair value of liability-classified warrants, the valuation of long-lived assets, including in-process research and development (IPR&D), patents and goodwill, accrued expenses and the recoverability of the Company's net deferred tax assets and related valuation allowance.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions. Cash equivalents include short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost plus accrued interest, which approximates fair market value.
Accounts Receivable	Accounts Receivable Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. As of December 31, 2015 and December 31, 2014 , management determined no allowance for doubtful accounts was required.
Property and Equipment	Property and Equipment Property and equipment consists of computer and laboratory equipment, software, office equipment, furniture and leasehold improvements and is recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company’s estimated useful life for property and equipment is as follows: Estimated Useful Lives Laboratory equipment 5 – 7 years Office and computer equipment 1 – 5 years Leasehold improvements Shorter of lease term or useful life The Company reviews long-lived assets when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded since inception.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid and other current assets consist primarily of prepaid insurance, Australian government research grants receivable, deferred licensing costs, and deposits.
In-Process Research & Development and Goodwill	In-Process Research & Development and Goodwill In-process research & development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized. The Company review s the carrying value of IPR&D and goodwill for potential impairment on an annual basis and at any time that events or business conditions indicate that it may be impaired. As permitted under Accounting Standards Codification Topic 350 (ASC 350), through December 31, 2015 , the Company elected to base its assessment of potential impairment on qualitative and quantitative factors , as applicable . The quantitative measure is based upon an estimate of future discounted cash flows. The discounted cash flows model indicates the fair value based on the present value of the cash flows expected to be generated in the future. Significant estimates in the discounted cash flows model include: the weighted average cost of capital; probability of success of research; expected future revenues from products; expected future operating costs; long-term rate of growth and profitability of the business; and working capital effects . Based on our assessment, IPR&D and goodwill were not impaired as of December 31, 2015 .
Patents	Patents Patents are recorded at fair value and are amortized using the straight-line method over their estimated useful lives. During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents were acquired by the Company and patents in the amount of $ 493,000 were recorded. These patents are amortized over their useful life through December 2026. Annual patent amortization expense for the years ending December 31 are estimated as follows: Patent Amortization 2016 $ 31,000 2017 31,000 2018 31,000 2019 31,000 2020 31,000 Thereafter 183,000 Total patent amortization expense $ 338,000
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based payments under the applicable accounting standard which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.
Warrant and Preferred Shares Conversion Feature Liability	Warrants and Preferred Shares Conversion Feature Liabilities The Company accounts for both warrants with anti-dilution adjustment provisions and other features and preferred share features with anti-dilution adjustment provisions under the applicable accounting guidance which requires the warrant and the preferred share features to be recorded as liabilities and adjusted to fair value at each reporting period.
Foreign Currency Translations and Transactions	Foreign Currency Translations and Transactions The functional currency of our wholly owned subsidiaries is the U.S. dollar.
Revenue Recognition	Revenue Recognition The Company generates revenue from technology licenses, collaborative research arrangements and agreements to provide research and development services. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees, royalties on product sales, and various other payments. The Company classifies advance payments received in excess of amounts earned as deferred revenue.
Research and Development Costs	Research and Development Costs Research and development costs include salaries, costs of outside collaborators and outside services, allocated facility, occupancy and utility expenses, which were partially offset by the benefit of Australian government research grants. The Company expenses research and development costs as incurred.
Income Taxes	Income Taxes Income taxes are recorded in accordance with the applicable accounting guidance which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the applicable accounting guidance. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2015 and 2014 , the Company does not have any significant uncertain tax positions.
Basic and Diluted Net Income (Loss) per Common Share	Basic and Diluted Net (Loss) Income per Common Share Basic net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders , less the impact under the two-class method of the preferred stockholders’ participation rights in the Company’s undistributed earnings, by the weighted average number of common shares outstanding during the period, excluding the dilutive effectors of preferred stock, warrants to purchase common shares, and stock options. Diluted net (loss) income per share of common stock is computed by dividing 1) the net (loss) income attributable to common stockholders, adjusted by income (loss) related to potential diluted preferred stock and warrants to purchase shares of our common stock by the sum of 2) the weighted average number of shares of common stock outstanding during the period plus the potential dilutive effects of preferred stock and warrants to purchase common stock and stock options outstanding during the period calculated in accordance with the treasury stock method, although these shares, options and warrants are excluded if their e ffect is anti-dilutive. T here was no difference between net loss and diluted net loss for the year ended December 31, 2015.
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss) The Company recorded no comprehensive income other than net income for the periods reported.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The ASU creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2017. The Company has not yet evaluated the potential impact of adopting the guidance on its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes . The ASU is part of a simplification initiative aimed at reducing complexity in accounting standards. Current GAAP requires the deferred taxes for each jurisdiction (or tax-paying component of a jurisdiction) to be presented as a net current asset or liability and net noncurrent asset or liability. To simplify presentation, the new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The standard is effective for public entities for annual reporting periods beginning after December 15, 2016, and interim periods therein. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company's results of operations or liquidity. In February 2015, the FASB issued ASU 2016-02, Leases (Topic 842) , which amends the FASB Accounting Standards Codification and creates Topic 842, "Leases." The new topic supersedes Topic 840, "Leases," and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018. ASU 2016-02 mandates a modified retrospective transition method. The Company has not yet evaluated the potential impact of adopting the guidance on its consolidated financial statements.

Significant Accounting Polici27

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Reconciliation of Restated Earnings Per Share Components	The table below illustrates a reconciliation of the components of the numerator and denominator included in the calculations of basic and diluted income (loss) per share and the impact of the correction of the error on the basic and diluted income (loss) per share amounts. Year Ended December 31, 2014 Basic income per share - as originally reported $ 5.82 Difference in basic income per share (1.61) Basic income per share - restated $ 4.21 Diluted loss per share - as originally reported $ 3.37 Difference in diluted loss per share (5.70) Diluted loss per share - restated $ (2.33) Numerator As originally reported $ 21,824,000 Correction - adjustment related to preferred stockholders' participation in the Company's undistributed earnings (6,067,000) Numerator for use in basic income per share, as restated 15,757,000 Correction - adjustments related to warrants and preferred stock (29,474,000) Numerator for use in diluted loss per share, as restated $ (13,717,000) Denominator As originally reported 6,472,093 Less antidilutive shares previously incorrectly included in denominator (585,363) Denominator for use in diluted loss per share, as restated 5,886,730
Useful Lives of Property and Equipment	The Company’s estimated useful life for property and equipment is as follows: Estimated Useful Lives Laboratory equipment 5 – 7 years Office and computer equipment 1 – 5 years Leasehold improvements Shorter of lease term or useful life
Annual Patent Amortization Expense	Annual patent amortization expense for the years ending December 31 are estimated as follows: Patent Amortization 2016 $ 31,000 2017 31,000 2018 31,000 2019 31,000 2020 31,000 Thereafter 183,000 Total patent amortization expense $ 338,000

Fair Value of Financial Asset28

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Derivatives And Fair Value [Line Items]
Financial Liabilities Measured at Fair Value	The following fair value hierarchy table presents information about each major category of the Company's financial liabilities measured at fair value on a recurring basis: Quoted Prices in Active Markets Significant Other Significant for Identical Observable Inputs Unobservable Items (Level 1) (Level 2) Inputs (Level 3) Total December 31, 2015 Liabilities Series B redeemable convertible preferred stock $ - $ - $ 1,493,000 $ 1,493,000 Warrant liability - - 6,000 6,000 Total liabilities $ - $ - $ 1,499,000 $ 1,499,000 December 31, 2014 Liabilities Series B redeemable convertible preferred stock $ - $ - $ 12,320,000 $ 12,320,000 Warrant liability - - 5,826,000 5,826,000 Total liabilities $ - $ - $ 18,146,000 $ 18,146,000
Changes in Fair Value of Derivative and Warrant Liability	The following table sets forth a summary of changes in the fair value of the Company's Series B redeemable convertible preferred stock derivative and warrant liabilities, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy, wherein fair value is estimated using significant unobservable inputs: Series B Warrant Redeemable Liability Preferred Stock Balance, December 31, 2014 $ 5,826,000 $ 12,320,000 Issuances 4,210,000 - Exercises (677,000) - Conversions to common stock - (1,497,000) Warrants reclassified from liabilities to equity due to amendment of warrants (5,462,000) - Warrants reclassified from liabilities to equity due to increase in authorized shares (3,281,000) - Changes in estimated fair value (610,000) (9,330,000) Balance as of December 31, 2015 $ 6,000 $ 1,493,000
Series B redeemable convertible preferred stock [Member]
Derivatives And Fair Value [Line Items]
Valuation Assumptions Used	The following assumptions were used at December 31, 2015 and December 31, 2014 : December 31, 2015 December 31, 2014 Volatility 108 to 117 % 91 % Expected term (years), weighted average 0.50 to 2.50 1.25 Risk-free interest rate 0.49 to 1.19 % 0.36 % Dividend yield 0.00 % 0.00 % Exercise price $ 7.00 $ 7.00 Common stock closing price $ 3.98 $ 10.50
Warrant [Member]
Derivatives And Fair Value [Line Items]
Valuation Assumptions Used	The following assumptions were used at December 31, 2015 and December 31, 2014 : December 31, 2015 December 31, 2014 Series (1) Series (1) June July December 2011 2011 2013 2013 2013 Volatility 112 % 155 % 155 % 155 % 151 % Expected term (years) 0.98 1.98 3.49 3.54 3.98 Risk-free interest rate 0.64 % 0.67 % 1.23 % 1.25 % 1.37 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % Exercise price $ 23.00 $ 23.00 $ 7.00 $ 7.00 $ 12.50 Common stock closing price $ 3.98 $ 10.50 $ 10.50 $ 10.50 $ 10.50 (1) See Note 11 – Warrants below for further description of the respective series of warrants.

Net (Loss) Income per Common 29

Net (Loss) Income per Common Share (Tables)	12 Months Ended
	Dec. 31, 2015
Net (Loss) Income per Common Share [Abstract]
Computation of Basic and Diluted Net Income (Loss) Per Share	The following table sets forth the computation of basic and diluted net (loss) income per share for the periods indicated (refer to Note 3 – Significant Accounting Policies for more information regarding the December 31, 2014 restatement): Year Ended December 31, 2015 Year Ended December 31, 2014 Net loss (Numerator) Shares (Denominator) Per share amount Net income (loss) (Numerator) Shares (Denominator) Per share amount Basic net (loss) income per common share: Net (loss) income and share amounts $ (516,000) 5,411,204 $ 23,109,000 3,746,639 Accretion of Series B redeemable convertible preferred stock (10,278,000) - (1,285,000) - Net (loss) income attributable to common stockholders (10,794,000) 5,411,204 21,824,000 3,746,639 Adjustment related to preferred stockholders' participation in the Company's undistributed earnings - - (6,067,000) - Basic (loss) income per share - restated for the year ended December 31, 2014 $ (10,794,000) 5,411,204 $ (1.99) $ 15,757,000 3,746,639 $ 4.21 Diluted net loss per common share: Accretion of Series B redeemable convertible preferred stock - - 1,285,000 - Adjustment related to preferred stockholders' participation in the Company's undistributed earnings - - 6,067,000 - Change in fair value of Series B stock derivative liability - - (27,760,000) - Dilutive shares related to Series B - - - 1,748,288 Change in fair value of warrant liability related to dilutive warrants - - (9,066,000) - Dilutive shares related to warrants - - - 391,803 Net loss attributable to common stockholders - diluted - restated for the year ended December 31, 2014 $ (10,794,000) 5,411,204 $ (1.99) $ (13,717,000) 5,886,730 $ (2.33)
Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding	The following outstanding securities at December 31, 2015 and 2014 have been excluded from the computation of diluted weighted shares outstanding for the years ended December 31, 2015 and 2014 , as they would have been anti-dilutive: December 31, 2014 2015 (restated) Options 669,769 440,695 Series B redeemable convertible preferred stock 7,527,853 - Warrants 656,211 167,711

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property and Equipment [Abstract]
Property and Equipment	Property and equipment consist of the following: December 31, 2015 2014 Laboratory equipment $ 1,494,000 $ 1,454,000 Office and computer equipment 53,000 59,000 Leasehold improvements 188,000 185,000 Total gross fixed assets 1,735,000 1,698,000 Less: accumulated depreciation and amortization (604,000) (478,000) Property and equipment, net $ 1,131,000 $ 1,220,000
Depreciation Expense	Depreciation expense totaled $ 299,000 and $ 127,000 for the years ended December 31, 2015 and 2014 , respectively.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Components of Deferred Tax Assets	Significant components of our deferred tax assets and liabilities are as follows: December 31, 2015 2014 Deferred tax assets/(liabilities) Net operating loss carry-forwards $ 65,425,000 $ 61,332,000 Research and orphan drug credit carry-forwards 5,181,000 3,855,000 Depreciation and amortization (3,000) (8,000) Stock options and other 479,000 1,381,000 Intangible assets (3,079,000) (3,155,000) Net deferred tax assets/(liabilities) 68,003,000 63,405,000 Valuation allowance for deferred tax assets (71,008,000) (66,483,000) Net deferred tax assets/(liabilities) $ (3,005,000) $ (3,078,000)
Reconciliation of Statutory to Effective Tax Rates	December 31, 2015 2014 Percent of pre-tax income: U.S. federal statutory income tax rate 34.0 % 34.0 % Warrant liability and preferred stock conversion liability 573.8 % (54.9) % Difference in foreign vs U.S. statutory rates (21.8) % - % Stock option forfeitures & expirations (138.2) % - % State taxes, net of federal benefit - % 3.7 % Non-deductible stock issuance costs (17.9) % - % R&D expenses associated with Australian research grants 27.8 % - % Effect of tax rate changes 12.4 % % All other (2.9) % 1.0 % Subtotal 467.2 % (16.2) % Change in valuation allowance (454.8) % 16.2 % Effective income tax rate 12.4 % 0.00 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Future Minimum Lease Payments	Future minimum lease payments, including termination fees, under noncancelable lease agreements as of December 31, 2015 , are as follows: Operating Lease 2016 $ 76,000 2017 39,000 2018 39,000 2019 5,000 Total minimum lease payments $ 159,000

Redeemable Convertible Prefer33

Redeemable Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Redeemable Convertible Preferred Stock
Schedule of Conversions of Series B Preferred to Common Stock	The following table summarizes the conversions of Series B shares to common stock pursuant to Series B stockholder elections during the year ended December 31, 2015 : Amount Reclassified Series B Common from Liability Conversion Shares Stock into Stockholders' Date Converted Issued Equity (1) April 8, 2015 107,100 21,420 $ 219,000 May 4, 2015 23,587 4,717 36,000 May 11, 2015 250,000 50,000 381,000 July 16, 2015 262,500 52,500 318,000 August 13, 2015 500,000 100,000 543,000 Totals 1,143,187 228,637 $ 1,497,000 (1) Not inclusive of $9 ,000 reclassified from Series B redeemable convertible preferred stock and liabilities for dividends payable of $368,000 upon conversion of these shares.

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2015
Warrants [Abstract]
Summary of Warrant Information	The following table provides a summary of warrants outstanding, issued or exercised for the year ended December 31, 2015 . Also included is the average exercise price per share and the aggregate proceeds to the Company if exercised as of December 31, 2015 . Series June 2013 and July 2013 March 2015 Series B Warrants December 2013 2013 Convertible Notes 2011 Totals Weighted Average Exercise Exercise Exercise Exercise Exercise Exercise Shares Price Shares Price Shares Price Shares Price Shares Price Shares Price Balance, December 31, 2014 - $ - 523,691 $ 7.00 86,408 $ 12.50 140,608 $ 7.00 27,103 $ 23.00 777,810 $ 8.00 Issuances 488,484 10.75 - - - - - - - - 488,484 10.75 Exercises - - (56,645) 7.00 - - - - - - (56,645) 7.00 Balance, December 31, 2015 488,484 $ 10.75 467,046 $ 7.00 86,408 $ 8.25 140,608 $ 7.00 27,103 $ 23.00 1,209,649 $ 8.96 Aggregate proceeds if exercised $ 5,251,203 $ 3,269,322 $ 712,866 $ 984,254 $ 623,369 $ 10,838,453

Stock Incentive Plan Compensa35

Stock Incentive Plan Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Stock Incentive Plan Compensation [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock option grants were as follows:
Allocation of Stock-Based Compensation Expenses	The estimated grant-date fair value of the Company’s stock-based awards is amortized ratably over the awards’ service periods. Stock-based compensation expense recognized was as follows: Year Ended December 31, 2015 2014 Research and development $ 122,000 $ 143,000 General and administrative 357,000 632,000 Severance charge 4,000 1,161,000 Total stock-based compensation expense $ 483,000 $ 1,936,000 (1) The severance charge component of stock incentive plan compensation relates to accelerated vesting of stock options held by the Company’s former Chief Executive Officer and a former executive per the terms of their employment agreements.
Summary of Stock Option Activity	The following table summarizes stock option activity for the year ended December 31, 2015 : Options Outstanding Average Weighted Remaining Shares Average Contractual Available Exercise Term Intrinsic For Grant Shares Price (Years) Value Balance, December 31, 2014 785,000 440,695 $ 9.37 8.18 $ 640,837 Increase in authorized shares 520,000 - - - - Granted (596,569) 596,569 8.47 - - Exercised - (214,815) 8.00 - (383,994) Forfeited 4,375 (4,812) 13.64 - - Expired 10,625 (147,868) 10.71 - - Balance, December 31, 2015 723,431 669,769 $ 8.68 9.29 $ - Vested or expected to vest at December 31, 2015 552,340 $ 10.03 9.21 $ - Exercisable at December 31, 2015 67,084 $ 10.03 6.71 $ -
Shares Reserved for Future Issuance	As of December 31, 2015 , the Company had reserved shares of its common stock for future issuance as follows: Shares Reserved Stock options outstanding 669,769 Available for future grants under the Stock Incentive Plan 723,431 Warrants 1,209,649 Total shares reserved 2,602,849

Severance Charge (Tables)

Severance Charge (Tables)	12 Months Ended
	Dec. 31, 2015
Severance Charge [Abstract]
Severance Charges	The severance accrual related to cash compensation and benefits as of December 31, 2014 and December 31, 2015 is as follows: Accrued severance, December 31, 2014 $ 555,000 Cash payments in 2015 (529,000) Additions in 2015 282,000 Accrued severance, December 31, 2015 $ 308,000

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Restatement of Prior Periods' Calculation of Diluted Income (Loss) Per Share	The Company corrected its calculation of basic and diluted income (loss) per share of common stock for the changes to net income (loss) and errors in the calculation of the weighted average diluted shares. The following tables present the impact of these corrections: Three Months Ended June 30, 2015 Three Months Ended September 30, 2014 Nine Months Ended September 30, 2014 Three Months Ended June 30, 2014 Six Months Ended June 30, 2014 Basic income per share - as originally reported $ 1.58 $ 5.58 $ 6.19 $ 3.69 $ 0.53 Difference in basic income per share (0.31) (1.71) (1.82) (1.13) (0.06) Basic income per share - restated $ 1.27 $ 3.87 $ 4.37 $ 2.56 $ 0.47 Diluted income per share - as originally reported $ 1.17 $ 3.30 $ 3.53 $ 2.09 $ 0.30 Difference in diluted loss per share (1.50) (4.16) (5.49) (2.72) (1.36) Diluted loss per share - restated $ (0.33) $ (0.86) $ (1.96) $ (0.63) $ (1.06) Numerator As originally reported $ 8,941,000 $ 20,884,000 $ 22,818,000 $ 13,555,000 $ 1,934,000 Correction - adjustment related to preferred stockholders' participation in the Company's undistributed earnings (1,716,000) (6,391,000) (6,703,000) (4,166,000) (202,000) Numerator for use in basic income per share, as restated $ 7,225,000 $ 14,493,000 $ 16,115,000 $ 9,389,000 $ 1,732,000 Correction - adjustment related to warrants and preferred stock (9,707,000) (19,459,000) (27,624,000) (13,131,000) (8,009,000) Numerator for use in diluted income (loss) per share, as restated $ (2,482,000) $ (4,966,000) $ (11,509,000) $ (3,742,000) $ (6,277,000) Denominator As originally reported 7,658,556 6,319,802 6,472,093 6,497,619 6,514,181 Less antidilutive shares previously incorrectly included in denominator (113,069) (532,898) (587,830) (591,594) (585,363) Denominator for use in diluted loss per share, as restated 7,545,487 5,786,904 5,884,263 5,906,025 5,928,818
Outstanding Securities Excluded from Computations of Diluted Weighted Shares Outstanding	The following table summarizes the outstanding securities that have been excluded from the computation of diluted weighted shares outstanding. Three Months Ended June 30, 2015 Three Months Ended September 30, 2014 Nine Months Ended September 30, 2014 Three Months Ended June 30, 2014 Six Months Ended June 30, 2014 Options, as restated 360,635 436,632 436,632 499,380 499,380 Warrants, as restated 167,711 167,711 140,608 140,608 140,608 Shares in escrow, as restated - 240,000 240,000 240,000 240,000 Total 528,346 844,343 817,240 879,988 879,988
Quarterly Financial Data	The following tables summarize the unaudited quarterly statements of operations for the Company for 2015 and 2014 . The tables include all necessary adjustments, consisting only of normal recurring adjustments necessary in the opinion of management for a fair statement of the results for interim periods. 2015 Three-Months Ended Three-Months Ended Three-Months Ended Three-Months Ended March 31, June 30, September 30, December 31, Revenue $ 102,000 $ 102,000 $ 143,000 $ 128,000 Total operating expenses 2,369,000 2,694,000 2,571,000 3,068,000 Loss from operations (2,267,000) (2,592,000) (2,428,000) (2,940,000) Other income (expense), net (12,226,000) 13,361,000 7,867,000 636,000 Income tax benefit - - - 73,000 Net (loss) income (14,493,000) 10,769,000 5,439,000 (2,231,000) Accretion of Series B redeemable convertible preferred stock (338,000) (1,828,000) (7,163,000) (949,000) Net (loss) income attributable to common stockholders (14,831,000) 8,941,000 (1,724,000) (3,180,000) Net (loss) income per share of common stock – basic - restated for the three months ended June 30, 2015 (3.49) 1.27 (0.30) (0.54) Net loss per share of common stock – diluted - restated for the three months ended June 30, 2015 (3.49) (0.33) (0.30) (0.54) 2014 Three-Months Ended Three-Months Ended Three-Months Ended Three-Months Ended March 31, June 30, September 30, December 31, (1) Revenue $ 104,000 $ 101,000 $ 103,000 $ 101,000 Total operating expenses 2,638,000 3,849,000 5,334,000 2,698,000 Loss from operations (2,534,000) (3,748,000) (5,231,000) (2,597,000) Other income (expense), net (8,773,000) 17,621,000 26,438,000 1,933,000 Income tax benefit - - - - Net (loss) income (11,307,000) 13,873,000 21,207,000 (664,000) Accretion of Series B redeemable convertible preferred stock (314,000) (318,000) (323,000) (330,000) Net (loss) income attributable to common stockholders (11,621,000) 13,555,000 20,884,000 (994,000) Net (loss) income per share of common stock – basic - restated for the three months ended June 30, 2014 and September 30, 2014 (3.18) 2.56 3.87 (0.25) Net loss per share of common stock – diluted - restated for the three months ended June 30, 2014 and September 30, 2014 (3.18) (0.63) (0.86) (0.44) (1) Not previously reported.

Organization and Description 38

Organization and Description of the Business (Details) - USD ($)	Mar. 16, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Retained earnings (accumulated deficit)			$ (362,522,000)	$ (362,006,000)
Proceeds from issuance of private placement, net of offering costs			$ 12,384,000
Private Placement [Member]
Proceeds from issuance of private placement, gross	$ 13,000,000	$ 13,000,000
Proceeds from issuance of private placement, net of offering costs		$ 12,400,000

Liquidity (Narrative) (Details)

Liquidity (Narrative) (Details) - USD ($)	12 Months Ended	60 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Liquidity [Abstract]
Retained earnings (accumulated deficit)	$ (362,522,000)	$ (362,522,000)	$ (362,006,000)
Retained earnings (accumulated deficit) during period		(47,000,000)
Cash and cash equivalents	$ 9,370,000	$ 9,370,000	$ 6,581,000	$ 20,355,000
Liquidity disclosure	Management believes that our existing resources will be sufficient to fund our planned operations through the third quarter of 2016.

Significant Accounting Polici40

Significant Accounting Policies (Narrative) (Details)	Aug. 03, 2015$ / sharesshares	Dec. 31, 2011USD ($)	Dec. 31, 2015$ / sharesshares	Aug. 02, 2015shares	Dec. 31, 2014$ / sharesshares
Reverse stock split, description	1-for-50 (1:50) reverse stock split of its common stock, par value $0.01 per share
Conversion ratio of reverse stock split	50
Common stock, shares authorized | shares	670,000,000		670,000,000	445,000,000	670,000,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Patents [Member]
Patents acquired | $		$ 493,000

Significant Accounting Polici41

Significant Accounting Policies (Calculation of Diluted Income (Loss) Per Share Error Correction) (Details) - USD ($)	3 Months Ended								6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share, Basic	$ (0.54)	$ (0.30)	$ 1.27	$ (3.49)	$ (0.25)	$ 3.87	$ 2.56	$ (3.18)	$ 0.47	$ 4.37	$ (1.99)	$ 4.21
Earnings Per Share, Diluted	$ (0.54)	$ (0.30)	$ (0.33)	$ (3.49)	$ (0.44)	$ (0.86)	$ (0.63)	$ (3.18)	$ (1.06)	$ (1.96)	$ (1.99)	$ (2.33)
Net income (loss), basic	$ (3,180,000)	$ (1,724,000)	$ 7,225,000	$ (14,831,000)	$ (994,000)	$ 14,493,000	$ 9,389,000	$ (11,621,000)	$ 1,732,000	$ 16,115,000	$ (10,794,000)	$ 15,757,000
Net income (loss), diluted			$ (2,482,000)			$ (4,966,000)	$ (3,742,000)		$ (6,277,000)	$ (11,509,000)	$ (10,794,000)	$ (13,717,000)
Weighted average number of shares of common stock outstanding - diluted			7,545,487			5,786,904	5,906,025		5,928,818	5,884,263	5,411,204	5,886,730
Scenario, Previously Reported [Member]
Earnings Per Share, Basic			$ 1.58			$ 5.58	$ 3.69		$ 0.53	$ 6.19		$ 5.82
Earnings Per Share, Diluted			$ 1.17			$ 3.30	$ 2.09		$ 0.30	$ 3.53		$ 3.37
Net income (loss), basic			$ 8,941,000			$ 20,884,000	$ 13,555,000		$ 1,934,000	$ 22,818,000		$ 21,824,000
Weighted average number of shares of common stock outstanding - diluted			7,658,556			6,319,802	6,497,619		6,514,181	6,472,093		6,472,093
Restatement Adjustment [Member]
Earnings Per Share, Basic			$ (0.31)			$ (1.71)	$ (1.13)		$ (0.06)	$ (1.82)		$ (1.61)
Earnings Per Share, Diluted			$ (1.50)			$ (4.16)	$ (2.72)		$ (1.36)	$ (5.49)		$ (5.70)
Net income (loss), basic			$ (1,716,000)			$ (6,391,000)	$ (4,166,000)		$ (202,000)	$ (6,703,000)		$ (6,067,000)
Net income (loss), diluted			$ (9,707,000)			$ (19,459,000)	$ (13,131,000)		$ (8,009,000)	$ (27,624,000)		$ (29,474,000)
Weighted average number of shares of common stock outstanding - diluted			(113,069)			(532,898)	(591,594)		(585,363)	(587,830)		(585,363)
Series B Convertible Preferred Stock [Member]
Weighted average number of shares of common stock outstanding - diluted												1,748,288

Significant Accounting Polici42

Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2015
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Shorter of lease term or useful life
Minimum [Member] | Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	1 year
Maximum [Member] | Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Maximum [Member] | Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Significant Accounting Polici43

Significant Accounting Policies (Estimated Annual Patent Amortization Expense) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Total patent amortization expense	$ 338,000	$ 369,000
Patents [Member]
2,016	31,000
2,017	31,000
2,018	31,000
2,019	31,000
2,020	31,000
Thereafter	183,000
Total patent amortization expense	$ 338,000

Fair Value of Financial Asset44

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Fair Value of Financial Liabilities Measured on Recurring Basis) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Preferred B stock conversion liability	$ 1,493,000	$ 12,320,000
Warrant liability	6,000	5,826,000
Total liabilities	1,499,000	18,146,000
Fair Value, Inputs, Level 3 [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Preferred B stock conversion liability	1,493,000	12,320,000
Warrant liability	6,000	5,826,000
Total liabilities	$ 1,499,000	$ 18,146,000

Fair Value of Financial Asset45

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Change in Fair Value of Series B Convertible Stock) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Derivatives And Fair Value [Line Items]
Balance, Warrant Liability	$ 5,826,000
Balance, Series B Redeemable Preferred Stock	12,320,000
Balance, Warrant Liability	6,000
Balance, Series B Redeemable Preferred Stock	1,493,000
Series B redeemable convertible preferred stock [Member]
Derivatives And Fair Value [Line Items]
Balance, Series B Redeemable Preferred Stock	12,320,000
Conversions to common stock	(1,497,000)
Changes in estimated fair value	(9,330,000)
Balance, Series B Redeemable Preferred Stock	1,493,000
Warrant [Member]
Derivatives And Fair Value [Line Items]
Balance, Warrant Liability	5,826,000
Issuance	4,210,000
Exercises	(677,000)
Warrants reclassified from liabilities to equity due to amendment of warrants	(5,462,000)
Warrants reclassified from liabilities to equity due to increase in authorized shares	(3,281,000)
Changes in estimated fair value	(610,000)
Balance, Warrant Liability	$ 6,000

Fair Value of Financial Asset46

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Valuation Assumptions for Warrants) (Details) - $ / shares		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
2011 [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Line Items]
Volatility	[1]	112.00%	155.00%
Expected term (years)	[1]	11 months 23 days	1 year 11 months 23 days
Risk-free interest rate	[1]	0.64%	0.67%
Dividend yield	[1]	0.00%	0.00%
Exercise price	[1]	$ 23	$ 23
Common stock closing price	[1]	$ 3.98	$ 10.50
June 2013 [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Line Items]
Volatility	[1]		155.00%
Expected term (years)	[1]		3 years 5 months 27 days
Risk-free interest rate	[1]		1.23%
Dividend yield	[1]		0.00%
Exercise price	[1]		$ 7
Common stock closing price	[1]		$ 10.50
July 2013 [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Line Items]
Volatility	[1]		155.00%
Expected term (years)	[1]		3 years 6 months 15 days
Risk-free interest rate	[1]		1.25%
Dividend yield	[1]		0.00%
Exercise price	[1]		$ 7
Common stock closing price	[1]		$ 10.50
December 2013 [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Line Items]
Volatility	[1]		151.00%
Expected term (years)	[1]		3 years 11 months 23 days
Risk-free interest rate	[1]		1.37%
Dividend yield	[1]		0.00%
Exercise price	[1]		$ 12.50
Common stock closing price	[1]		$ 10.50
[1]	See Note 11 - Warrants below for further description of the respective series of warrants.

Fair Value of Financial Asset47

Fair Value of Financial Assets and Liabilities - Derivative Instruments (Valuation Assumptions Used for Series B Convertible Stock) (Details) - Series B redeemable convertible preferred stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Volatility		91.00%
Fair Value Assumptions, Expected Term		1 year 3 months
Risk-free interest rate		0.36%
Dividend yield	0.00%	0.00%
Exercise price	$ 7	$ 7
Common stock closing price	$ 3.98	$ 10.50
Minimum [Member]
Volatility	108.00%
Fair Value Assumptions, Expected Term	6 months
Risk-free interest rate	0.49%
Maximum [Member]
Volatility	117.00%
Fair Value Assumptions, Expected Term	2 years 6 months
Risk-free interest rate	1.19%

Net Income (Loss) Per Share (Co

Net Income (Loss) Per Share (Computation of Diluted Net Loss Per Share Error Correction) (Details) - USD ($)	3 Months Ended								6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Net income (loss)	$ (2,231,000)	$ 5,439,000	$ 10,769,000	$ (14,493,000)	$ (664,000)	$ 21,207,000	$ 13,873,000	$ (11,307,000)			$ (516,000)	$ 23,109,000
Net Income (Loss) Available to Common Stockholders, Basic	$ (3,180,000)	$ (1,724,000)	$ 7,225,000	$ (14,831,000)	$ (994,000)	$ 14,493,000	$ 9,389,000	$ (11,621,000)	$ 1,732,000	$ 16,115,000	$ (10,794,000)	$ 15,757,000
Weighted Average Number of Shares Outstanding, Basic											5,411,204	3,746,639
Earnings Per Share, Basic	$ (0.54)	$ (0.30)	$ 1.27	$ (3.49)	$ (0.25)	$ 3.87	$ 2.56	$ (3.18)	$ 0.47	$ 4.37	$ (1.99)	$ 4.21
Change in fair value of warrant liability related to dilutive warrants												$ (9,066,000)
Dilutive shares												6,067,000
Change in fair value of Series B preferred stock derivative liability											$ (9,330,000)	$ (27,764,000)
Accretion of Series B redeemable convertible preferred stock	$ 949,000	$ 7,163,000	$ 1,828,000	$ 338,000	$ 330,000	$ 323,000	$ 318,000	$ 314,000			10,278,000	1,285,000
Net Income (Loss) Available to Common Stockholders, Diluted			$ (2,482,000)			$ (4,966,000)	$ (3,742,000)		$ (6,277,000)	$ (11,509,000)	$ (10,794,000)	$ (13,717,000)
Weighted Average Number of Shares Outstanding, Diluted			7,545,487			5,786,904	5,906,025		5,928,818	5,884,263	5,411,204	5,886,730
Earnings Per Share, Diluted	$ (0.54)	$ (0.30)	$ (0.33)	$ (3.49)	$ (0.44)	$ (0.86)	$ (0.63)	$ (3.18)	$ (1.06)	$ (1.96)	$ (1.99)	$ (2.33)
Warrant [Member]
Weighted Average Number of Shares Outstanding, Diluted												391,803
Series B Convertible Preferred Stock [Member]
Change in fair value of Series B preferred stock derivative liability											$ (9,330,000)	$ (27,760,000)
Accretion of Series B redeemable convertible preferred stock											$ (10,278,000)	$ 1,285,000
Weighted Average Number of Shares Outstanding, Diluted												1,748,288
Scenario, Previously Reported [Member]
Net Income (Loss) Available to Common Stockholders, Basic			$ 8,941,000			$ 20,884,000	$ 13,555,000		$ 1,934,000	$ 22,818,000		$ 21,824,000
Weighted Average Number of Shares Outstanding, Basic												3,746,639
Earnings Per Share, Basic			$ 1.58			$ 5.58	$ 3.69		$ 0.53	$ 6.19		$ 5.82
Weighted Average Number of Shares Outstanding, Diluted			7,658,556			6,319,802	6,497,619		6,514,181	6,472,093		6,472,093
Earnings Per Share, Diluted			$ 1.17			$ 3.30	$ 2.09		$ 0.30	$ 3.53		$ 3.37
Restatement Adjustment [Member]
Net Income (Loss) Available to Common Stockholders, Basic			$ (1,716,000)			$ (6,391,000)	$ (4,166,000)		$ (202,000)	$ (6,703,000)		$ (6,067,000)
Earnings Per Share, Basic			$ (0.31)			$ (1.71)	$ (1.13)		$ (0.06)	$ (1.82)		$ (1.61)
Adjustment related to preferred stockholders' participation in the Company's undistributed earnings												(6,067,000)
Net Income (Loss) Available to Common Stockholders, Diluted			$ (9,707,000)			$ (19,459,000)	$ (13,131,000)		$ (8,009,000)	$ (27,624,000)		$ (29,474,000)
Weighted Average Number of Shares Outstanding, Diluted			(113,069)			(532,898)	(591,594)		(585,363)	(587,830)		(585,363)
Earnings Per Share, Diluted			$ (1.50)			$ (4.16)	$ (2.72)		$ (1.36)	$ (5.49)		$ (5.70)
Restatement Adjustment [Member] | Series B Convertible Preferred Stock [Member]
Accretion of Series B redeemable convertible preferred stock												$ (1,285,000)

Net Income (Loss) per Common Sh

Net Income (Loss) per Common Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details) - shares	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	528,346	844,343	879,988	879,988	817,240
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	360,635	436,632	499,380	499,380	436,632	669,769	440,695
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	167,711	167,711	140,608	140,608	140,608	656,211	167,711
Escrow [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		240,000	240,000	240,000	240,000

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property and Equipment [Abstract]
Depreciation	$ 299,000	$ 127,000

Property and Equipment (Composi

Property and Equipment (Composition of Property and Equipment) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Total gross fixed assets	$ 1,735,000	$ 1,698,000
Less: accumulated depreciation and amortization	(604,000)	(478,000)
Property, Plant and Equipment, Net, Total	1,131,000	1,220,000
Laboratory Equipment [Member]
Total gross fixed assets	1,494,000	1,454,000
Office and Computer Equipment [Member]
Total gross fixed assets	53,000	59,000
Leasehold Improvements [Member]
Total gross fixed assets	$ 188,000	$ 185,000

Property and Equipment (Propert

Property and Equipment (Property and Equipment Rollforward) (Details)	Dec. 31, 2015USD ($)
Property and Equipment [Abstract]
Property, Plant and Equipment, Gross, Beginning Balance	$ 1,698,000
Property, Plant and Equipment, Gross, Ending Balance	1,735,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance	(478,000)
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance	(604,000)
Property, Plant and Equipment, Net, Beginning Balance	1,220,000
Property, Plant and Equipment, Net, Ending Balance	$ 1,131,000

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Net operating loss carryforwards ("NOLs")	$ 182,300,000
Operating loss carryforward, expiration date	Dec. 31, 2019
Interest and penalties pertaining to income tax examination recognized	$ 0	$ 0
Maximum [Member]
Income tax examination, years under examination	2,015
Minimum [Member]
Income tax examination, years under examination	1,998
Domestic Tax Authority [Member]
Tax credit carryforward, expiration date	Dec. 31, 2019
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax credit carryforward	$ 5,200,000
Foreign Tax Authority [Member]
Net operating loss carryforwards ("NOLs")	8,500,000
Tax Year 2015 [Member] | Foreign Tax Authority [Member]
Net operating loss carryforwards ("NOLs")	$ 3,000,000

Income Taxes (Components of Def

Income Taxes (Components of Deferred Tax Assets) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Net operating loss carry-forwards	$ 65,425,000	$ 61,332,000
Research and orphan drug credit carry-forwards	5,181,000	3,855,000
Depreciation and amortization	(3,000)	(8,000)
Stock options and other	479,000	1,381,000
Intangible Assets	(3,079,000)	(3,155,000)
Deferred Tax Assets, Gross, Total	68,003,000	63,405,000
Valuation allowance for deferred tax assets	(71,008,000)	(66,483,000)
Deferred Tax Assets, Net, Total	$ (3,005,000)	$ (3,078,000)

Income Taxes (Reconciliation of

Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
U.S. federal statutory income tax rate	34.00%	34.00%
Warrant liability and preferred stock conversion liability	573.80%	(54.90%)
Difference in foreign vs U.S. statutory rates	(21.80%)
Stock option forfeitures & expirations	(138.20%)
State taxes, net of federal benefit		3.70%
Non-deductible stock issuance costs	(17.90%)
R&D expenses associated with Australian research grants	27.80%
Effect of tax rate changes	12.40%
All other	(2.90%)	1.00%
Subtotal	467.20%	(16.20%)
Change in valuation allowance	(454.80%)	16.20%
Effective income tax rate	12.40%	0.00%

Commitments and Contingencies56

Commitments and Contingencies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Rent expense under operating leases	$ 192,000	$ 314,000
Minimum payment commitment	159,000
Virginia Biotech Research Partnership Laboratory [Member]
Minimum payment commitment	14,000
Virginia Biotech Research Partnership Office Space [Member]
Minimum payment commitment	18,000
Savills Studley San Diego Office Space [Member]
Minimum payment commitment	5,000
Avtotehna [Member]
Monthly rental expense	3,244
Minimum payment commitment	$ 122,000
Leasehold improvements		$ 185,000
Lease expiration date	Feb. 1, 2019

Commitments and Contingencies57

Commitments and Contingencies (Future Minimum Lease Payments) (Details)	Dec. 31, 2015USD ($)
Commitments and Contingencies [Abstract]
2,016	$ 76,000
2,017	39,000
2,018	39,000
2,019	5,000
Total minimum lease payments	$ 159,000

Collaborative and Other Agree58

Collaborative and Other Agreements (Narrative) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Licensing Payments Received	$ 128,000	$ 143,000	$ 102,000	$ 102,000	$ 101,000	$ 103,000	$ 101,000	$ 104,000	$ 475,000	$ 409,000
Intrexon Corporation [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Value of common stock paid for technology access fee											$ 3,000,000
Fees Payable Upon Commencement Of The First Phase 2 Trial	2,500,000								2,500,000
Fees Payable Upon First Regulatory Approval	$ 5,000,000								5,000,000
Expenses Incurred Under Channel Collaborative Agreement									178,000	862,000
Cash Paid For Channel Collaboration Agreement									125,000	941,000
University Of Leicester [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expenses Under Collaborative Agreement									265,000	232,000
Cash Paid For Collaboration Agreement									$ 290,000	182,000
Collaborative Agreement Expiration Date									Nov. 12, 2018
University Of Glasgow [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expenses Under Collaborative Agreement									$ 61,000	184,000
Walter Reed Army Institute Of Research [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments For Services Under Collaborative Agreement									0	$ 207,000
Takara Bio Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Licensing Payments Received									$ 40,000
Takara Bio Inc [Member] | Nonsoftware License Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of License Product Sales Receivable									12.00%
Percent of License Product Service Revenues Receivable									6.00%
Minimum Annual Royalty Payments Receivable									$ 15,000
Takara Bio Inc [Member] | Nonsoftware License Arrangement [Member] | Criteria One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent Licensing Receivable									30,000
Licensed Product Revenues Milestone Benchmark									1,000,000
Takara Bio Inc [Member] | Nonsoftware License Arrangement [Member] | Criteria Two [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent Licensing Receivable									40,000
Licensed Product Net Sales Milestone Benchmark									$ 2,000,000

Redeemable Convertible Prefer59

Redeemable Convertible Preferred Stock (Details)		Aug. 13, 2015USD ($)shares	Aug. 03, 2015	Jul. 16, 2015USD ($)shares	May. 11, 2015USD ($)shares	May. 04, 2015USD ($)shares	Apr. 08, 2015USD ($)shares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)$ / sharesshares
Class of Stock [Line Items]
Change in fair value of Preferred B stock derivative liability								$ 9,330,000	$ 27,764,000
Preferred B stock conversion liability								1,493,000	12,320,000
Amount reclassified to Series B redeemable convertible stock								$ (8,971,000)
Reverse stock split, description			1-for-50 (1:50) reverse stock split of its common stock, par value $0.01 per share
Conversion ratio of reverse stock split			50
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares										10,000,000
Preferred Stock, initial stated value per share | $ / shares										$ 1.40
Preferred Stock, par value per share | $ / shares										$ 0.01
Number of common stock shares into which each share of preferred stock can be converted										0.20
Proceeds from conversion of Series B convertible stock										$ 7,000,000
Preferred Stock dividend rate								10.00%
Trigger price per share for redemption and conversion features of embedded derivative | $ / shares								$ 7
Number of shares converted | shares		500,000		262,500	250,000	23,587	107,100	1,143,187
Shares of common stock issued upon conversion of preferred stock | shares		100,000		52,500	50,000	4,717	21,420	228,637
Amount reclassified from Series B derivative liability into shareholders' equity	[1]	$ 543,000		$ 318,000	$ 381,000	$ 36,000	$ 219,000	$ 1,497,000
Change in fair value of Preferred B stock derivative liability								9,330,000	$ 27,760,000
Preferred B stock conversion liability								1,493,000
Amount reclassified to Series B redeemable convertible stock								8,971,000
Dividends payable								$ 368,000
[1]	Not inclusive of $9,000 reclassified from Series B redeemable convertible preferred stock and liabilities for dividends payable of $368,000 upon conversion of these shares.

Redeemable Convertible Prefer60

Redeemable Convertible Preferred Stock (Schedule of Conversions of Series B to Common Stock) (Details) - Series B Convertible Preferred Stock [Member] - USD ($)		Aug. 13, 2015	Jul. 16, 2015	May. 11, 2015	May. 04, 2015	Apr. 08, 2015	Dec. 31, 2015
Number of shares converted		500,000	262,500	250,000	23,587	107,100	1,143,187
Shares of common stock issued upon conversion of preferred stock		100,000	52,500	50,000	4,717	21,420	228,637
Amount reclassified from Series B derivative liability into shareholders' equity	[1]	$ 543,000	$ 318,000	$ 381,000	$ 36,000	$ 219,000	$ 1,497,000
[1]	Not inclusive of $9,000 reclassified from Series B redeemable convertible preferred stock and liabilities for dividends payable of $368,000 upon conversion of these shares.

Warrants (Narrative) (Details)

Warrants (Narrative) (Details)

Aug. 03, 2015USD ($)shares

Apr. 29, 2015USD ($)shares

Apr. 01, 2015USD ($)shares

Mar. 16, 2015USD ($)$ / sharesshares

Dec. 31, 2013$ / sharesshares

Jul. 15, 2013USD ($)$ / sharesshares

Mar. 31, 2015USD ($)

May. 31, 2013$ / sharesshares

Dec. 31, 2015USD ($)$ / sharesshares

Dec. 31, 2014USD ($)shares

Aug. 02, 2015shares

May. 08, 2015USD ($)

Dec. 22, 2011$ / sharesshares

Class of Warrant or Right [Line Items]

Sale of stock, price per share | $ / shares

$ 3.98

Warrant expiration date

February through May 2018

Warrant liability

$ 6,000

$ 5,826,000

Amount reclassified from warrant liability into equity

$ 3,281,000

$ 46,000

$ 630,000

$ 5,462,000

Reverse stock split, description

1-for-50 (1:50) reverse stock split of its common stock, par value $0.01 per share

Conversion ratio of reverse stock split

50

Common stock, shares authorized | shares

670,000,000

670,000,000

670,000,000

445,000,000

Fair value of liquidated damages reclassified to shareholders' equity

$ 120,000

Gain (loss) on remeasurement of fair value of warrant liability

$ 610,000

$ 9,455,000

Warrant issuance expense

(213,000)

Series March 2015 Warrants [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

393,939

Exercise price of warrants | $ / shares

$ 10.75

Series B Placement - June 26, 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant liability

$ 4,285,000

Warrants exercised | shares

4,525

52,120

Shares issued upon exercise of warrants | shares

4,525

52,120

Series B Placement - July 15, 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant liability

$ 674,000

Placement Agent [Member]

Class of Warrant or Right [Line Items]

Warrant liability

$ 814,000

Other expenses related to issuance of warrants

$ 213,000

$ 218,000

Down Round Position [Member]

Class of Warrant or Right [Line Items]

Exercise price of warrants | $ / shares

$ 8.25

Biocontrol Business Combination [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

27,103

Exercise price of warrants | $ / shares

$ 23

Warrant expiration date

December 2,016

Convertible Notes Payable [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

140,608

Exercise price of warrants | $ / shares

$ 7

Private Placement [Member]

Class of Warrant or Right [Line Items]

Sale of stock, number of shares issued in transaction | shares

1,575,758

1,440,140

Sale of stock, price per share | $ / shares

$ 8.25

$ 12.50

Warrant liability

$ 4,210,000

Other expenses related to issuance of warrants

$ 213,000

Private Placement [Member] | Series March 2015 Warrants [Member]

Class of Warrant or Right [Line Items]

Exercise price of warrants | $ / shares

$ 10.75

Warrant expiration date

March 2,020

Warrant liquidation charges if warrants not exercised according to terms

$ 2,500,000

Warrant liability

$ 3,396,000

Private Placement [Member] | Series December 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

86,408

Exercise price of warrants | $ / shares

$ 12.50

Warrant expiration date

December 2,018

Private Placement [Member] | Placement Agent [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

94,545

Exercise price of warrants | $ / shares

$ 10.75

Private Placement - Series B Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Number of securities called by warrants | shares

600,805

Exercise price of warrants | $ / shares

$ 7

Private Placement - Series B Preferred Stock [Member] | Series B Placement - June 26, 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant expiration date

June 2,018

Private Placement - Series B Preferred Stock [Member] | Series B Placement - July 15, 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant expiration date

July 2,018

Private Placement - Series B Preferred Stock [Member] | Placement Agent [Member]

Class of Warrant or Right [Line Items]

Warrant issuance expense

$ 759,000

Warrants (Number of Warrants, E

Warrants (Number of Warrants, Exercise Price, Aggregate Proceeds of Warrants if Exercised) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issuances	4,210,000
Shares, Balance at December 31, 2015	1,209,649
Warrants Through March 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issuances	488,484
Shares, Balance at December 31, 2015	488,484
Aggregate proceeds if exercised | $	$ 5,251,203
Weighted Average Exercise Price, Issuances | $ / shares	$ 10.75
Weighted Average Exercise Price, Outstanding at December 31, 2015 | $ / shares	$ 10.75
2013 Series B Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	523,691
Shares, Exercises	(56,645)
Shares, Balance at December 31, 2015	467,046
Aggregate proceeds if exercised | $	$ 3,269,322
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 7
Weighted Average Exercise Price, Exercises | $ / shares	7
Weighted Average Exercise Price, Outstanding at December 31, 2015 | $ / shares	$ 7
Warrants Through December 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	86,408
Shares, Balance at December 31, 2015	86,408
Aggregate proceeds if exercised | $	$ 712,866
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 12.50
Weighted Average Exercise Price, Outstanding at December 31, 2015 | $ / shares	$ 8.25
Convertible Promissory Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	140,608
Shares, Balance at December 31, 2015	140,608
Aggregate proceeds if exercised | $	$ 984,254
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 7
Weighted Average Exercise Price, Outstanding at December 31, 2015 | $ / shares	$ 7
Warrants Through 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	27,103
Shares, Balance at December 31, 2015	27,103
Aggregate proceeds if exercised | $	$ 623,369
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 23
Weighted Average Exercise Price, Outstanding at December 31, 2015 | $ / shares	$ 23
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Balance at December 31, 2014	777,810
Shares, Issuances	488,484
Shares, Exercises	(56,645)
Shares, Balance at December 31, 2015	1,209,649
Aggregate proceeds if exercised | $	$ 10,838,453
Weighted Average Exercise Price, Outstanding at December 31, 2014 | $ / shares	$ 8
Weighted Average Exercise Price, Issuances | $ / shares	10.75
Weighted Average Exercise Price, Exercises | $ / shares	7
Weighted Average Exercise Price, Outstanding at December 31, 2015 | $ / shares	$ 8.96

Stock Incentive Plan Compensa63

Stock Incentive Plan Compensation (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Closing stock price	$ 3.98
Intrinsic value of options outstanding		$ 640,837
Weighted average exercise price of options outstanding	$ 10.03
Options granted in stock option grant	596,569
Exercise price of options granted	$ 8.47
Unrecognized compensation cost related to unvested options	$ 3,600,000
Weighted-average remaining period for recognition of compensation costs related to unvested options	6 years 8 months 16 days
Board Members and Executives [Member]
Options granted in stock option grant	596,569
Exercise price of options granted	$ 8.47
Chief Executive Officer [Member]
Options granted in stock option grant	399,716
Exercise price of options granted	$ 9.45

Stock Incentive Plan Compensa64

Stock Incentive Plan Compensation (Stock Option Valuation Assumptions) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Series B redeemable convertible preferred stock [Member]
Risk-free interest rate		0.36%
Volatility		91.00%
Fair Value Assumptions, Expected Term		1 year 3 months
Dividend yield	0.00%	0.00%
Exercise price	$ 7	$ 7
Common stock closing price	$ 3.98	$ 10.50
Common Stock Options [Member]
Risk-free interest rate		1.30%
Volatility	139.00%	160.90%
Fair Value Assumptions, Expected Term		4 years
Dividend yield	0.00%	0.00%
Minimum [Member] | Series B redeemable convertible preferred stock [Member]
Risk-free interest rate	0.49%
Volatility	108.00%
Fair Value Assumptions, Expected Term	6 months
Minimum [Member] | Common Stock Options [Member]
Risk-free interest rate	1.55%
Fair Value Assumptions, Expected Term	6 years
Maximum [Member] | Series B redeemable convertible preferred stock [Member]
Risk-free interest rate	1.19%
Volatility	117.00%
Fair Value Assumptions, Expected Term	2 years 6 months
Maximum [Member] | Common Stock Options [Member]
Risk-free interest rate	1.78%
Fair Value Assumptions, Expected Term	10 years

Stock Incentive Plan Compensa65

Stock Incentive Plan Compensation (Allocation of Stock-Based Compensation Expense) (Details) - USD ($)		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense		$ 483,000	$ 1,936,000
Employee Severance [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	[1]	4,000	1,161,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense		122,000	143,000
General and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense		$ 357,000	$ 632,000
[1]	(1)The severance charge component of stock incentive plan compensation relates to accelerated vesting of stock options held by the Company's former Chief Executive Officer and a former executive per the terms of their employment agreements.

Stock Incentive Plan Compensa66

Stock Incentive Plan Compensation (Summary of Stock Option Activity) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Stock Incentive Plan Compensation [Abstract]
Shares Available for Grant, Balance at December 31, 2014	785,000
Shares Available for Grant, Increase in authorized shares	520,000
Shares Available for Grant, Granted	(596,569)
Shares Available for Grant, Exercised
Shares Available for Grant, Forfeited	4,375
Shares Available for Grant, Expired	10,625
Shares Available for Grant, Balance at December 31, 2015	723,431	785,000
Shares, Balance at December 31, 2014	440,695
Shares, Granted	596,569
Shares, Exercises	(214,815)
Shares, Forfeited	(4,812)
Shares, Expired	(147,868)
Shares, Balance at December 31, 2015	669,769	440,695
Shares, Vested or expected to vest at December 31, 2015	552,340
Shares, Exercisable at December 30, 2015	67,084
Weighted Average Exercise Price, Outstanding at December 31, 2014	$ 9.37
Weighted Average Exercise Price, Granted	8.47
Weighted Average Exercise Price, Exercised	8
Weighted Average Exercise Price, Forfeited	13.64
Weighted Average Exercise Price, Expired	10.71
Weighted Average Exercise Price, Outstanding at December 31, 2015	8.68	$ 9.37
Weighted Average Exercise Price, Vested or expected to vest at December 31, 2015	10.03
Weighted Average Exercise Price, Exercisable at December 31, 2015	$ 10.03
Average Remaining Contractual Term (Years), Outstanding	9 years 3 months 15 days	8 years 2 months 5 days
Average Remaining Contractual Term (Years), Vested or expected to vest at December 31, 2015	9 years 2 months 16 days
Average Remaining Contractual Term (Years), Exercisable at December 31, 2015	6 years 8 months 16 days
Intrinsic Value, Outstanding at December 31, 2014	$ 640,837
Intrinsic Value, Exercised	$ (383,994)
Intrinsic Value, Outstanding at December 31, 2015		$ 640,837

Stock Incentive Plan Compensa67

Stock Incentive Plan Compensation (Shares Reserved for Future Issuance) (Details) - shares	Dec. 31, 2015	Dec. 31, 2014
Stock Incentive Plan Compensation [Abstract]
Stock options outstanding	669,769	440,695
Available for future grants under the Stock Incentive Plan	723,431	785,000
Warrants	1,209,649
Total shares reserved	2,602,849

Related Parties (Details)

Related Parties (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current liabilities due to related parties	$ 56,000	$ 3,000
Intrexon Corporation [Member]
Value of common stock paid for technology access fee			$ 3,000,000
Fees payable upon commencement of first Phase 2 trial	2,500,000
Fees payable upon first regulatory approval	5,000,000
Cash paid for channel collaboration agreement	$ 125,000	$ 941,000

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Details) - USD ($)	Mar. 16, 2015	Mar. 31, 2015	Dec. 31, 2013	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Sale of stock, price per share					$ 3.98
Warrant liability					$ 6,000	$ 5,826,000
Placement Agent [Member]
Class of Stock [Line Items]
Fees paid to placement agent	$ 833,000
Warrant liability	$ 814,000
Other expenses related to issuance of warrants				$ 213,000	218,000
Series March 2015 Warrants [Member]
Class of Stock [Line Items]
Number of securities called by warrants	393,939
Exercise price of warrants	$ 10.75
Decrease to additional paid-in capital resulting from warrants issued					$ 3,996,000
Private Placement [Member]
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction	1,575,758		1,440,140
Sale of stock, price per share	$ 8.25		$ 12.50
Proceeds from issuance of private placement, gross	$ 13,000,000	$ 13,000,000
Warrant liability	4,210,000
Other expenses related to issuance of warrants	$ 213,000
Private Placement [Member] | Placement Agent [Member]
Class of Stock [Line Items]
Number of securities called by warrants	94,545
Exercise price of warrants	$ 10.75
Private Placement [Member] | Series March 2015 Warrants [Member]
Class of Stock [Line Items]
Exercise price of warrants	$ 10.75
Warrant liability	$ 3,396,000

Severance Charge (Narrative) (D

Severance Charge (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Severance Charge [Abstract]
Severance charge	$ 289,000	$ 1,864,000

Severance Charge (Severance Acc

Severance Charge (Severance Accrual) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Severance Charge [Abstract]
Accrued severance, December 31, 2014	$ 555,000
Payments in 2015	(529,000)
Additions in 2015	282,000
Accrued severance, September 30, 2015	$ 308,000

Quarterly Financial Data (Impac

Quarterly Financial Data (Impact of Error Correction on Calculation of Diluted Earnings Per Share) (Details) - USD ($)	3 Months Ended								6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share, Basic	$ (0.54)	$ (0.30)	$ 1.27	$ (3.49)	$ (0.25)	$ 3.87	$ 2.56	$ (3.18)	$ 0.47	$ 4.37	$ (1.99)	$ 4.21
Earnings Per Share, Diluted	$ (0.54)	$ (0.30)	$ (0.33)	$ (3.49)	$ (0.44)	$ (0.86)	$ (0.63)	$ (3.18)	$ (1.06)	$ (1.96)	$ (1.99)	$ (2.33)
Net income (loss), basic	$ (3,180,000)	$ (1,724,000)	$ 7,225,000	$ (14,831,000)	$ (994,000)	$ 14,493,000	$ 9,389,000	$ (11,621,000)	$ 1,732,000	$ 16,115,000	$ (10,794,000)	$ 15,757,000
Net income (loss), diluted			$ (2,482,000)			$ (4,966,000)	$ (3,742,000)		$ (6,277,000)	$ (11,509,000)	$ (10,794,000)	$ (13,717,000)
Weighted average number of shares of common stock outstanding - diluted			7,545,487			5,786,904	5,906,025		5,928,818	5,884,263	5,411,204	5,886,730
Scenario, Previously Reported [Member]
Earnings Per Share, Basic			$ 1.58			$ 5.58	$ 3.69		$ 0.53	$ 6.19		$ 5.82
Earnings Per Share, Diluted			$ 1.17			$ 3.30	$ 2.09		$ 0.30	$ 3.53		$ 3.37
Net income (loss), basic			$ 8,941,000			$ 20,884,000	$ 13,555,000		$ 1,934,000	$ 22,818,000		$ 21,824,000
Weighted average number of shares of common stock outstanding - diluted			7,658,556			6,319,802	6,497,619		6,514,181	6,472,093		6,472,093
Restatement Adjustment [Member]
Earnings Per Share, Basic			$ (0.31)			$ (1.71)	$ (1.13)		$ (0.06)	$ (1.82)		$ (1.61)
Earnings Per Share, Diluted			$ (1.50)			$ (4.16)	$ (2.72)		$ (1.36)	$ (5.49)		$ (5.70)
Net income (loss), basic			$ (1,716,000)			$ (6,391,000)	$ (4,166,000)		$ (202,000)	$ (6,703,000)		$ (6,067,000)
Net income (loss), diluted			$ (9,707,000)			$ (19,459,000)	$ (13,131,000)		$ (8,009,000)	$ (27,624,000)		$ (29,474,000)
Weighted average number of shares of common stock outstanding - diluted			(113,069)			(532,898)	(591,594)		(585,363)	(587,830)		(585,363)
Series B Convertible Preferred Stock [Member]
Weighted average number of shares of common stock outstanding - diluted												1,748,288

Quarterly Financial Data (Resta

Quarterly Financial Data (Restated Antidilutive Securities Excluded from Computation of Diluted Shares Outstanding) (Details) - shares	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	528,346	844,343	879,988	879,988	817,240
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	360,635	436,632	499,380	499,380	436,632	669,769	440,695
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	167,711	167,711	140,608	140,608	140,608	656,211	167,711
Escrow [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		240,000	240,000	240,000	240,000

Quarterly Financial Data (Selec

Quarterly Financial Data (Selected Quarterly Financial Data) (Details) - USD ($)	3 Months Ended								6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 128,000	$ 143,000	$ 102,000	$ 102,000	$ 101,000	$ 103,000	$ 101,000	$ 104,000			$ 475,000	$ 409,000
Total operating expenses	3,068,000	2,571,000	2,694,000	2,369,000	2,698,000	5,334,000	3,849,000	2,638,000			10,702,000	14,519,000
Loss from operations	(2,940,000)	(2,428,000)	(2,592,000)	(2,267,000)	(2,597,000)	(5,231,000)	(3,748,000)	(2,534,000)			(10,227,000)	(14,110,000)
Other income (expense), net	636,000	7,867,000	13,361,000	(12,226,000)							9,638,000	37,219,000
Other income					1,933,000	26,438,000	17,621,000
Other expense								(8,773,000)			(302,000)
Income tax benefit	73,000										73,000
Net (loss) income	(2,231,000)	5,439,000	10,769,000	(14,493,000)	(664,000)	21,207,000	13,873,000	(11,307,000)			(516,000)	23,109,000
Accretion of Series B redeemable convertible preferred stock	(949,000)	(7,163,000)	(1,828,000)	(338,000)	(330,000)	(323,000)	(318,000)	(314,000)			(10,278,000)	(1,285,000)
Net (loss) income attributable to common stockholders	$ (3,180,000)	$ (1,724,000)	$ 7,225,000	$ (14,831,000)	$ (994,000)	$ 14,493,000	$ 9,389,000	$ (11,621,000)	$ 1,732,000	$ 16,115,000	$ (10,794,000)	$ 15,757,000
Net (loss) income per share of common stock - basic	$ (0.54)	$ (0.30)	$ 1.27	$ (3.49)	$ (0.25)	$ 3.87	$ 2.56	$ (3.18)	$ 0.47	$ 4.37	$ (1.99)	$ 4.21
Net (loss) income per share of common stock - diluted	$ (0.54)	$ (0.30)	$ (0.33)	$ (3.49)	$ (0.44)	$ (0.86)	$ (0.63)	$ (3.18)	$ (1.06)	$ (1.96)	$ (1.99)	$ (2.33)
Scenario, Previously Reported [Member]
Net (loss) income attributable to common stockholders			$ 8,941,000			$ 20,884,000	$ 13,555,000		$ 1,934,000	$ 22,818,000		$ 21,824,000
Net (loss) income per share of common stock - basic			$ 1.58			$ 5.58	$ 3.69		$ 0.53	$ 6.19		$ 5.82
Net (loss) income per share of common stock - diluted			$ 1.17			$ 3.30	$ 2.09		$ 0.30	$ 3.53		$ 3.37

Subsequent Events (Details)

Subsequent Events (Details) - Novolytics Ltd [Member] - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2016	Dec. 31, 2015
Description of exercise term of warrants granted		The warrants will expire upon the later of the close of business of the 24-month anniversary of the date the warrants first become exercisable, as described in the preceding sentence, or the 24-month anniversary of the initial effectiveness of a registration statement covering the exercise shares.
Subsequent Event [Member]
Cash consideration for assets acquired	$ 146,000
Number of securities called by warrants	170,000
Exercise price of warrants	$ 12
Expiration term of warrants, period following effective date of warrants	24 months
Subsequent Event [Member] | Share-based Compensation Award, Tranche One [Member]
Vesting description of shares called by warrants granted	One half of the shares subject to the warrant become exercisable on the date that is the earlier of 30 days following the expiration of the lock-up period for our next public offering, or December 31, 2016.
Percent of shares vesting	50.00%
Subsequent Event [Member] | Share-based Compensation Award, Tranche Two [Member]
Vesting description of shares called by warrants granted	The remaining shares subject to the warrant become exercisable 60 days thereafter.
Percent of shares vesting	50.00%